Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | CCR1 | P32246 | 2/20 | 0.44 |
| ▸ | CCR5 | P51681 | 2/20 | 0.44 |
| ▸ | CCR8 | P51685 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | METAP1 | P53582 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.44 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.44 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | PI4KA | P42356 | 1/20 | 0.41 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.41 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.41 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31734268 | 1.00 | KDM4E (0.44) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL16261706 | 0.90 | ALDH1A1 (0.37) | KDM4ELMNACCR1CCR5CCR8 | |
| Pyridine SCHEMBL29143197 | 0.89 | KDM4E (0.35) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL670301 | 0.84 | KDM4E (0.42) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL10416676 | 0.83 | NOS3 (0.43) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL5577241 | 0.83 | KDM4E (0.41) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL11121873 | 0.83 | NOS3 (0.43) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL19435589 | 0.83 | KDM4E (0.41) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL6502675 | 0.83 | KDM4E (0.41) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL27936240 | 0.83 | KDM4E (0.41) | KDM4ELMNACCR1CCR5CCR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 609 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118638097-A | Preparation of diaryl thiohydantoin Process for the preparation of ureide compounds | 阿拉贡药品公司 | 2024-09-13 | — | — | CN | claimed |
| CN-107108507-B | Process for preparing diaryl thiohydantoin compounds | 阿拉贡药品公司 | 2024-05-28 | — | — | CN | claimed |
| CN-117832456-A | Preparation method of rare earth doped amorphous carbon coated silicon-carbon composite material | 云南坤天新能源有限公司 | 2024-04-05 | — | — | CN | claimed |
| US-10723714-B2 | Processes for the preparation of a diarylthiohydantoin compound | ARAGON PHARMACEUTICALS, INC. (US) | 2020-07-28 | — | — | US | claimed |
| US-20190284156-A1 | Processes For The Preparation Of A Diarylthiohydantoin Compound | ARAGON PHARMACEUTICALS INC (US) | 2019-09-19 | — | — | US | claimed |
| US-10316015-B2 | Processes for the preparation of a diarylthiohydantoin compound | ARAGON PHARMACEUTICALS, INC. (US) | 2019-06-11 | — | — | US | claimed |
| US-20190135775-A9 | PROCESSES FOR THE PREPARATION OF A DIARYLTHIOHYDANTOIN COMPOUND | ARAGON PHARMACEUTICALS, INC. | 2019-05-09 | — | — | US | claimed |
| EP-3233803-B1 | PROCESS FOR THE PREPARATION OF A DIARYLTHIOHYDANTOIN COMPOUND | ARAGON PHARMACEUTICALS INC (US) | 2019-01-30 | — | — | EP | claimed |
| US-20180002309-A1 | PROCESSES FOR THE PREPARATION OF A DIARYLTHIOHYDANTOIN COMPOUND | ARAGON PHARMACEUTICALS INC (US) | 2018-01-04 | — | — | US | claimed |
| EP-3233823-A1 | PROCESSES FOR THE PREPARATION OF A DIARYLTHIOHYDANTOIN COMPOUND | Aragon Pharmaceuticals, Inc. (US) | 2017-10-25 | — | — | EP | claimed |
| EP-3233803-A2 | PROCESS FOR THE PREPARATION OF A DIARYLTHIOHYDANTOIN COMPOUND | Aragon Pharmaceuticals, Inc. (US) | 2017-10-25 | — | — | EP | claimed |
| US-9688655-B2 | Process for the preparation of a diarylthiohydantoin compound | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-27 | — | — | US | claimed |
| WO-2016100645-A1 | PROCESSES FOR THE PREPARATION OF A DIARYLTHIOHYDANTOIN COMPOUND | ARAGON PHARMACEUTICALS, INC. (US) | 2016-06-23 | — | — | WO | claimed |
| WO-2016100652-A2 | PROCESS FOR THE PREPARATION OF A DIARYLTHIOHYDANTOIN COMPOUND | ARAGON PHARMACEUTICALS, INC. (US) | 2016-06-23 | — | — | WO | claimed |
| US-20160176844-A1 | PROCESSES FOR THE PREPARATION OF A DIARYLTHIOHYDANTOIN COMPOUND | JANSSEN PHARMACEUTICA NV (BE) | 2016-06-23 | — | — | US | claimed |
| US-20160176845-A1 | PROCESS FOR THE PREPARATION OF A DIARYLTHIOHYDANTOIN COMPOUND | JANSSEN PHARMACEUTICA NV (BE) | 2016-06-23 | — | — | US | claimed |
| EP-2170872-B1 | PROCESS FOR THE PREPARATION OF THE N-(2-CHLORO-4-METHYL-3-THIENYL)-1H- BENZIMIDAZOL-2-AMINE HYDROCHLORIDE AND INTERMEDIATES THEREOF | SANOFI AVENTIS US LLC (US) | 2010-09-01 | — | — | EP | claimed |
| EP-0457250-B1 | Novel bifunctional linking compounds, conjugates and methods for their production | BRISTOL MYERS SQUIBB CO (US) | 1999-07-14 | — | — | EP | claimed |
| WO-1992006081-A1 | ANILIDE DERIVATIVES WITH ANGIOTENSIN II ANTAGONIST PROPERTIES | WARNER-LAMBERT COMPANY (US) | 1992-04-16 | — | — | WO | claimed |
| US-12595415-B2 | Aromatic isothiocyanates | MERCK PATENT GMBH (DE) | 2026-04-07 | — | — | US | disclosed |
| US-12570647-B2 | Amino benzothiazole compounds for treatment of antibiotic resistant bacteria | SAINT LOUIS UNIVERSITY (US) | 2026-03-10 | — | — | US | disclosed |
| EP-4692083-A1 | NOVEL AZABICYCLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR INHIBITING AUTOTAXIN, COMPRISING SAME | Nextgen Bioscience Co., Ltd. (KR) | 2026-02-11 | — | — | EP | disclosed |
| US-20260034252-A1 | FIBROBLAST ACTIVATION PROTEIN-TARGETED COMPOSITIONS AND METHODS OF USE THEREOF | RATIO THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-12534669-B2 | Isothiocyanatoethynylbenzene derivatives | MERCK PATENT GMBH (DE) | 2026-01-27 | — | — | US | disclosed |
| US-20250376432-A1 | PROCESS FOR PREPARING MODULATORS OF EUKARYOTIC INITIATION FACTOR 2B | DENALI THERAPEUTICS INC (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250360218-A1 | MITOCHONDRIA-TARGETING CANCER THERAPEUTIC COMPOSITION | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2025-11-27 | — | — | US | disclosed |
| EP-4653434-A1 | CRYSTALLINE SALT OF MACROPA-(OCH2CH2)-PH-NCS | Bayer Aktiengesellschaft (DE) | 2025-11-26 | — | — | EP | disclosed |
| EP-4314194-B1 | AROMATIC ISOTHIOCYANATES | MERCK PATENT GMBH (DE) | 2025-09-10 | — | — | EP | disclosed |
| EP-4263751-B1 | HETEROAROMATIC ISOTHIOCYANATES | MERCK PATENT GMBH (DE) | 2025-08-13 | — | — | EP | disclosed |
| US-12378224-B2 | Heteroaryl compounds and their use as Mer inhibitors | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2025-08-05 | — | — | US | disclosed |
| US-12359128-B2 | Heteroaromatic isothiocyanates | MERCK PATENT GMBH (DE) | 2025-07-15 | — | — | US | disclosed |
| US-20250214985-A1 | MACROCYCLIC COMPLEXES OF ALPHA-EMITTING RADIONUCLIDES AND THEIR USE IN TARGETED RADIOTHERAPY OF CANCER | CORNELL UNIVERSITY (US) | 2025-07-03 | — | — | US | disclosed |
| US-20250206737-A1 | PROCESS FOR PREPARING TUCATINIB AND ITS HEMIETHANOLATE | SCINOPHARM TAIWAN, LTD. (TW) | 2025-06-26 | — | — | US | disclosed |
| US-20250179364-A1 | ISOTHIOCYANATOETHYNYLBENZENE DERIVATIVES | MERCK PATENT GMBH (DE) | 2025-06-05 | — | — | US | disclosed |
| EP-4263750-B1 | HETEROAROMATIC ISOTHIOCYANATES | MERCK PATENT GMBH (DE) | 2025-06-04 | — | — | EP | disclosed |
| EP-4561998-A1 | FIBROBLAST ACTIVATION PROTEIN-TARGETED COMPOSITIONS AND METHODS OF USE THEREOF | Ratio Therapeutics, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| US-20250163040-A1 | MACROCYCLIC COMPLEXES OF ALPHA-EMITTING RADIONUCLIDES AND THEIR USE IN TARGETED RADIOTHERAPY OF CANCER | CORNELL UNIVERSITY (US) | 2025-05-22 | — | — | US | disclosed |
| US-12297386-B2 | Aromatic isothiocyanates | MERCK PATENT GMBH (DE) | 2025-05-13 | — | — | US | disclosed |
| EP-4543843-A1 | PROCESS FOR PREPARING MODULATORS OF EUKARYOTIC INITIATION FACTOR 2B | Denali Therapeutics Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| EP-4237508-B1 | AROMATIC ISOTHIOCYANATES | MERCK PATENT GMBH (DE) | 2025-04-30 | — | — | EP | disclosed |
| EP-4237507-B1 | AROMATIC ISOTHIOCYANATES | MERCK PATENT GMBH (DE) | 2025-04-30 | — | — | EP | disclosed |
| US-12258339-B2 | Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer | CORNELL UNIVERSITY (US) | 2025-03-25 | — | — | US | disclosed |
| CN-119630634-A | Method for preparing modulators of eukaryotic initiation factor 2B | 戴纳立制药公司 | 2025-03-14 | — | — | CN | disclosed |
| CN-114502691-B | Fluorinated aromatic compounds | 默克专利股份有限公司 | 2025-02-25 | — | — | CN | disclosed |
| CN-116507695-B | Aromatic isothiocyanates | 默克专利股份有限公司 | 2025-02-25 | — | — | CN | disclosed |
| CN-116601265-B | Aromatic isothiocyanates | 默克专利股份有限公司 | 2025-02-25 | — | — | CN | disclosed |
| WO-2025029608-A1 | FIBROBLAST ACTIVATION PROTEIN-TARGETED COMPOSITIONS AND METHODS OF USE THEREOF | RATIO THERAPEUTICS, INC. (US) | 2025-02-06 | — | — | WO | disclosed |
| US-12216113-B2 | Method for preparing analysis sample, analysis method, and kit for preparing analysis sample | SHIMADZU CORPORATION (JP) | 2025-02-04 | — | — | US | disclosed |
| EP-3541804-B1 | CYCLOALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC (US) | 2025-01-22 | — | — | EP | disclosed |
| US-12203023-B2 | Aromatic isothiocyanates | MERCK PATENT GMBH (DE) | 2025-01-21 | — | — | US | disclosed |
| EP-3541802-B1 | ALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC (US) | 2025-01-01 | — | — | EP | disclosed |
| WO-2024260902-A1 | LIQUID CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 2024-12-26 | — | — | WO | disclosed |
| WO-2024205327-A1 | NOVEL AZABICYCLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR INHIBITING AUTOTAXIN, COMPRISING SAME | 주식회사 넥스트젠바이오사이언스 | 2024-10-03 | — | — | WO | disclosed |
| US-12103922-B2 | Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer | CORNELL UNIVERSITY (US) | 2024-10-01 | — | — | US | disclosed |
| CN-118638097-A | Preparation of diaryl thiohydantoin Process for the preparation of ureide compounds | 阿拉贡药品公司 | 2024-09-13 | — | — | CN | disclosed |
| CN-114829543-B | Aromatic isothiocyanates | 默克专利股份有限公司 | 2024-09-10 | — | — | CN | disclosed |
| US-12077703-B2 | Heteroaromatic isothiocyanates | MERCK PATENT GMBH (DE) | 2024-09-03 | — | — | US | disclosed |
| WO-2024175615-A1 | DIHYDRONAPTHALENE DERIVATIVES | MERCK PATENT GMBH (DE) | 2024-08-29 | — | — | WO | disclosed |
| CN-111295444-B | Polynomial coding for oligonucleotide-directed combinatorial chemistry | 哈斯达克科学公司 | 2024-08-09 | — | — | CN | disclosed |
| CN-118434716-A | Isothiocyanoethynyl benzene derivatives | 默克专利股份有限公司 | 2024-08-02 | — | — | CN | disclosed |
| WO-2024134973-A1 | COMPOUND, AND LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTAL DISPLAY ELEMENT, SENSOR, LIQUID CRYSTAL LENS, OPTICAL COMMUNICATION DEVICE AND ANTENNA EACH USING SAME | DIC株式会社 | 2024-06-27 | — | — | WO | disclosed |
| US-20240199957-A1 | AROMATIC ISOTHIOCYANATES | MERCK PATENT GMBH (DE) | 2024-06-20 | — | — | US | disclosed |
| EP-4073205-B1 | AROMATIC ISOTHIOCYANATES | MERCK PATENT GMBH (DE) | 2024-06-12 | — | — | EP | disclosed |
| CN-107108507-B | Process for preparing diaryl thiohydantoin compounds | 阿拉贡药品公司 | 2024-05-28 | — | — | CN | disclosed |
| US-11964933-B2 | Fluorinated aromatic compounds | MERCK PATENT GMBH (DE) | 2024-04-23 | — | — | US | disclosed |
| US-20240124779-A1 | HETEROAROMATIC ISOTHIOCYANATES | MERCK PATENT GMBH (DE) | 2024-04-18 | — | — | US | disclosed |
| US-20240124780-A1 | HETEROAROMATIC ISOTHIOCYANATES | MERCK PATENT GMBH (DE) | 2024-04-18 | — | — | US | disclosed |
| EP-4041846-B1 | FLUORINATED AROMATIC COMPOUNDS | MERCK PATENT GMBH (DE) | 2024-04-17 | — | — | EP | disclosed |
| US-20240117249-A1 | AROMATIC ISOTHIOCYANATES | MERCK PATENT GMBH (DE) | 2024-04-11 | — | — | US | disclosed |
| CN-117832456-A | Preparation method of rare earth doped amorphous carbon coated silicon-carbon composite material | 云南坤天新能源有限公司 | 2024-04-05 | — | — | CN | disclosed |
| EP-4022007-B1 | AROMATIC ISOTHIOCYANATES | MERCK PATENT GMBH (DE) | 2024-04-03 | — | — | EP | disclosed |
| US-20240072425-A1 | AROMATIC ISOTHIOCYANATES | MERCK PATENT GMBH (DE) | 2024-02-29 | — | — | US | disclosed |
| EP-4314194-A2 | AROMATIC ISOTHIOCYANATES | Merck Patent GmbH (DE) | 2024-02-07 | — | — | EP | disclosed |
| US-11891557-B2 | Isothiocyanato tolane derivatives | MERCK PATENT GMBH (DE) | 2024-02-06 | — | — | US | disclosed |
| WO-2024026072-A1 | FIBROBLAST ACTIVATION PROTEIN-TARGETED COMPOSITIONS AND METHODS OF USE THEREOF | RATIO THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| WO-2024026072-A1 | FIBROBLAST ACTIVATION PROTEIN-TARGETED COMPOSITIONS AND METHODS OF USE THEREOF | RATIO THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| WO-2023250107-A1 | PROCESS FOR PREPARING MODULATORS OF EUKARYOTIC INITIATION FACTOR 2B | DENALI THERAPEUTICS INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| US-20230392075-A1 | AROMATIC ISOTHIOCYANATES | MERCK PATENT GMBH (DE) | 2023-12-07 | — | — | US | disclosed |
| US-20230392076-A1 | AROMATIC ISOTHIOCYANATES | MERCK PATENT GMBH (DE) | 2023-12-07 | — | — | US | disclosed |
| US-11834599-B2 | Aromatic isothiocyanates | MERCK PATENT GMBH (DE) | 2023-12-05 | — | — | US | disclosed |
| WO-2023220671-A1 | PRODRUGS USEFUL FOR REDUCING ANTHRACYCLINE CARDIOTOXICITY | WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023220671-A1 | PRODRUGS USEFUL FOR REDUCING ANTHRACYCLINE CARDIOTOXICITY | WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) | 2023-11-16 | — | — | WO | disclosed |
| CN-117043304-A | Aromatic isothiocyanates | 默克专利股份有限公司 | 2023-11-10 | — | — | CN | disclosed |
| EP-4263750-A1 | HETEROAROMATIC ISOTHIOCYANATES | Merck Patent GmbH (DE) | 2023-10-25 | — | — | EP | disclosed |
| EP-4263751-A1 | HETEROAROMATIC ISOTHIOCYANATES | Merck Patent GmbH (DE) | 2023-10-25 | — | — | EP | disclosed |
| US-11795580-B2 | Molecules for verifying oligonucleotide directed combinatorial synthesis and methods of making and using the same | HAYSTACK SCIENCES CORPORATION (US) | 2023-10-24 | — | — | US | disclosed |
| US-20230313044-A1 | COMPOUND, COMPOSITION, LIQUID CRYSTAL COMPOSITION, AND DEVICE | DIC CORPORATION (JP) | 2023-10-05 | — | — | US | disclosed |
| US-20230313044-A1 | COMPOUND, COMPOSITION, LIQUID CRYSTAL COMPOSITION, AND DEVICE | DIC CORPORATION (JP) | 2023-10-05 | — | — | US | disclosed |
| EP-4237508-A1 | AROMATIC ISOTHIOCYANATES | Merck Patent GmbH (DE) | 2023-09-06 | — | — | EP | disclosed |
| EP-4237507-A1 | AROMATIC ISOTHIOCYANATES | Merck Patent GmbH (DE) | 2023-09-06 | — | — | EP | disclosed |
| EP-4237509-A1 | AROMATIC ISOTHIOCYANATES | Merck Patent GmbH (DE) | 2023-09-06 | — | — | EP | disclosed |
| WO-2023163553-A1 | MITOCHONDRIA-TARGETING CANCER THERAPEUTIC COMPOSITION | 서울대학교산학협력단 | 2023-08-31 | — | — | WO | disclosed |
| US-11739265-B2 | Aromatic isothiocyanates | MERCK PATENT GMBH (DE) | 2023-08-29 | — | — | US | disclosed |
| CN-116601265-A | Aromatic isothiocyanates | 默克专利股份有限公司 | 2023-08-15 | — | — | CN | disclosed |
| CN-116583578-A | Heteroaromatic isothiocyanates | 默克专利股份有限公司 | 2023-08-11 | — | — | CN | disclosed |
| CN-116583577-A | Heteroaromatic isothiocyanates | 默克专利股份有限公司 | 2023-08-11 | — | — | CN | disclosed |
| CN-116507695-A | Aromatic isothiocyanates | 默克专利股份有限公司 | 2023-07-28 | — | — | CN | disclosed |
| CN-116490591-A | Aromatic isothiocyanates | 默克专利股份有限公司 | 2023-07-25 | — | — | CN | disclosed |
| EP-4204515-A1 | AROMATIC ISOTHIOCYANATES | Merck Patent GmbH (DE) | 2023-07-05 | — | — | EP | disclosed |
| CN-111065712-B | Isothiocyanate diphenyl acetylene derivative | 默克专利股份有限公司 | 2023-07-04 | — | — | CN | disclosed |
| WO-2023117724-A1 | ISOTHIOCYANATOETHYNYLBENZENE DERIVATIVES | MERCK PATENT GMBH (DE) | 2023-06-29 | — | — | WO | disclosed |
| US-11661580-B2 | Method of inhibiting tau phosphorylation | CASSAVA SCIENCES, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-11661580-B2 | Method of inhibiting tau phosphorylation | CASSAVA SCIENCES, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| CN-116018389-A | Aromatic isothiocyanates | 默克专利股份有限公司 | 2023-04-25 | — | — | CN | disclosed |
| US-20230104326-A1 | AROMATIC ISOTHIOCYANATES | MERCK PATENT GMBH (DE) | 2023-04-06 | — | — | US | disclosed |
| EP-4159795-A1 | THERAPEUTIC CONJUGATES WITH SULFATED DENDRIMERS FOR INTRACELLULAR TARGETING | ICD-Therapeutics GmbH (DE) | 2023-04-05 | — | — | EP | disclosed |
| CN-115820806-A | Combinatorial synthesis of oligonucleotide directed and recorded coded probe molecules | 哈斯达克科学公司 | 2023-03-21 | — | — | CN | disclosed |
| EP-3294714-B1 | MORPHINAN DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN | NEKTAR THERAPEUTICS (US) | 2023-03-15 | — | — | EP | disclosed |
| US-20230025385-A1 | FLUORINATED AROMATIC COMPOUNDS | MERCK PATENT GMBH (DE) | 2023-01-26 | — | — | US | disclosed |
| EP-4087621-A1 | MACROCYCLIC CHELATES AND USES THEREOF | Fusion Pharmaceuticals Inc. (CA) | 2022-11-16 | — | — | EP | disclosed |
| EP-3733816-B1 | ISOTHIOCYANATO-TOLANES | MERCK PATENT GMBH (DE) | 2022-11-16 | — | — | EP | disclosed |
| CN-115243729-A | Macrocyclic chelates and their use | 融合制药公司 | 2022-10-25 | — | — | CN | disclosed |
| EP-4073205-A1 | AROMATIC ISOTHIOCYANATES | Merck Patent GmbH (DE) | 2022-10-19 | — | — | EP | disclosed |
| WO-2022207584-A2 | AROMATIC ISOTHIOCYANATES | MERCK PATENT GMBH (DE) | 2022-10-06 | — | — | WO | disclosed |
| CN-109312492-B | Combinatorial synthesis of oligonucleotide directed and recorded coded probe molecules | 哈斯达克科学公司 | 2022-10-04 | — | — | CN | disclosed |
| US-20220306938-A1 | AROMATIC ISOTHIOCYANATES | MERCK PATENT GMBH (DE) | 2022-09-29 | — | — | US | disclosed |
| US-20220274974-A1 | MACROCYCLIC COMPLEXES OF ALPHA-EMITTING RADIONUCLIDES AND THEIR USE IN TARGETED RADIOTHERAPY OF CANCER | CORNELL UNIVERSITY (US) | 2022-09-01 | — | — | US | disclosed |
| US-11427761-B2 | Isothiocyanato compounds, including tolanes | MERCK PATENT GMBH (DE) | 2022-08-30 | — | — | US | disclosed |
| US-20220267312-A1 | AMINO BENZOTHIAZOLE COMPOUNDS FOR TREATMENT OF ANTIBIOTIC RESISTANT BACTERIA | SAINT LOUIS UNIVERSITY (US) | 2022-08-25 | — | — | US | disclosed |
| WO-2022176961-A1 | COMPOUND AND METAL COMPLEX | 住友化学株式会社 | 2022-08-25 | — | — | WO | disclosed |
| WO-2022176954-A1 | RADIOACTIVE METAL COMPLEX AND METHOD FOR PRODUCING SAME, AND RADIOACTIVE METAL SCAVENGER | 住友化学株式会社 | 2022-08-25 | — | — | WO | disclosed |
| EP-4041846-A1 | FLUORINATED AROMATIC COMPOUNDS | Merck Patent GmbH (DE) | 2022-08-17 | — | — | EP | disclosed |
| CN-114829543-A | Aromatic isothiocyanates | 默克专利股份有限公司 | 2022-07-29 | — | — | CN | disclosed |
| US-11385221-B2 | Alzheimer's disease assay in a living patient | PAIN THERAPEUTICS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| EP-4022007-A1 | AROMATIC ISOTHIOCYANATES | Merck Patent GmbH (DE) | 2022-07-06 | — | — | EP | disclosed |
| WO-2022128845-A1 | HETEROAROMATIC ISOTHIOCYANATES | MERCK PATENT GMBH (DE) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022129018-A1 | HETEROAROMATIC ISOTHIOCYANATES | MERCK PATENT GMBH (DE) | 2022-06-23 | — | — | WO | disclosed |
| US-20220185803-A1 | MACROCYCLIC COMPLEXES OF ALPHA-EMITTING RADIONUCLIDES AND THEIR USE IN TARGETED RADIOTHERAPY OF CANCER | CORNELL UNIVERSITY (US) | 2022-06-16 | — | — | US | disclosed |
| US-20220177461-A1 | MACROCYCLIC COMPLEXES OF ALPHA-EMITTING RADIONUCLIDES AND THEIR USE IN TARGETED RADIOTHERAPY OF CANCER | CORNELL UNIVERSITY (US) | 2022-06-09 | — | — | US | disclosed |
| US-20220154179-A1 | OLIGONUCLEOTIDE DIRECTED AND RECORDED COMBINITORIAL SYNTHESIS OF ENCODED PROBE MOLECULES | HAYSTACK SCIENCES CORPORATION (US) | 2022-05-19 | — | — | US | disclosed |
| CN-114502691-A | Fluorinated aromatic compounds | 默克专利股份有限公司 | 2022-05-13 | — | — | CN | disclosed |
| WO-2022090099-A1 | AROMATIC ISOTHIOCYANATES | MERCK PATENT GMBH (DE) | 2022-05-05 | — | — | WO | disclosed |
| WO-2022090109-A1 | AROMATIC ISOTHIOCYANATES | MERCK PATENT GMBH (DE) | 2022-05-05 | — | — | WO | disclosed |
| WO-2022090098-A1 | AROMATIC ISOTHIOCYANATES | MERCK PATENT GMBH (DE) | 2022-05-05 | — | — | WO | disclosed |
| CN-114302872-A | Aromatic isothiocyanates | 默克专利股份有限公司 | 2022-04-08 | — | — | CN | disclosed |
| EP-3372585-B1 | PROCESS FOR THE PREPARATION OF A DIARYLTHIOHYDANTOIN COMPOUND | ARAGON PHARMACEUTICALS INC (US) | 2022-03-30 | — | — | EP | disclosed |
| US-11289661-B2 | Nitrogen-containing heterocyclic compounds for organic light emitting devices | IDEMITSU KOSAN CO., LTD. (JP) | 2022-03-29 | — | — | US | disclosed |
| US-11279698-B2 | Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer | CORNELL UNIVERSITY (US) | 2022-03-22 | — | — | US | disclosed |
| US-20220073822-A1 | LIQUID-CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 2022-03-10 | — | — | US | disclosed |
| WO-2022043376-A1 | AROMATIC ISOTHIOCYANATES | MERCK PATENT GMBH (DE) | 2022-03-03 | — | — | WO | disclosed |
| EP-3145984-B1 | THERAPEUTIC CONJUGATES WITH SULFATED DENDRIMERS FOR INTRACELLULAR TARGETING | ICD THERAPEUTICS GMBH (DE) | 2022-02-23 | — | — | EP | disclosed |
| US-20220000841-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | UNIVERSITÉ DE MONTPELLIER (FR) | 2022-01-06 | — | — | US | disclosed |
| US-20210395281-A1 | MACROCYCLIC CHELATES AND USES THEREOF | OXFORD FINANCE LLC | 2021-12-23 | — | — | US | disclosed |
| US-20210389298-A1 | Alzheimer's Disease Assay in a Living Patient | PAIN THERAPEUTICS, INC. (US) | 2021-12-16 | — | — | US | disclosed |
| US-11186836-B2 | Oligonucleotide directed and recorded combinatorial synthesis of encoded probe molecules | HAYSTACK SCIENCES CORPORATION (US) | 2021-11-30 | — | — | US | disclosed |
| CN-113056288-A | Macrocyclic complexes of radionuclides and their use in radiotherapy of cancer | 康奈尔大学 | 2021-06-29 | — | — | CN | disclosed |
| US-11045560-B2 | Therapeutic conjugates with sulfated dendrimers for intracellular targeting | ICD-THERAPEUTICS GMBH (DE) | 2021-06-29 | — | — | US | disclosed |
| US-11040953-B2 | Process for the preparation of a diarylthiohydantoin compound | ARAGON PHARMACEUTICALS, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| US-20210164989-A1 | METHOD FOR PREPARING ANALYSIS SAMPLE, ANALYSIS METHOD, AND KIT FOR PREPARING ANALYSIS SAMPLE | SHIMADZU CORPORATION (JP) | 2021-06-03 | — | — | US | disclosed |
| EP-3812767-A1 | METHOD FOR PREPARING ANALYSIS SAMPLE, ANALYSIS METHOD, AND KIT FOR PREPARING ANALYSIS SAMPLE | SHIMADZU CORPORATION (JP) | 2021-04-28 | — | — | EP | disclosed |
| US-20210095248-A1 | METHOD OF INHIBITING TAU PHOSPHORYLATION | PAIN THERAPEUTICS, INC. | 2021-04-01 | — | — | US | disclosed |
| EP-3372584-B9 | PROCESS FOR THE PREPARATION OF A DIARYLTHIOHYDANTOIN COMPOUND | ARAGON PHARMACEUTICALS INC (US) | 2021-03-31 | — | — | EP | disclosed |
| EP-3791875-A1 | METHOD FOR INHIBITING GROWTH OF CANCER CELLS | Pain Therapeutics, Inc. (US) | 2021-03-17 | — | — | EP | disclosed |
| US-10934282-B2 | Heteroaromatic modulators of the retinoid-related orphan receptor gamma | LEO PHARMA A/S (DK) | 2021-03-02 | — | — | US | disclosed |
| US-10899754-B2 | Modulators of indoleamine 2,3-dioxygenase | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-01-26 | — | — | US | disclosed |
| EP-3541803-B1 | TRIAZOLE PYRIDYL COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC (US) | 2020-12-23 | — | — | EP | disclosed |
| US-10865186-B2 | Opioid agonists and uses thereof | NEKTAR THERAPEUTICS (US) | 2020-12-15 | — | — | US | disclosed |
| US-20200354334-A1 | Process For The Preparation Of A Diarylthiohydantoin Compound | ARAGON PHARMACEUTICALS INC (US) | 2020-11-12 | — | — | US | disclosed |
| CN-111848474-A | Isothiocyanato-tolanes | 默克专利股份有限公司 | 2020-10-30 | — | — | CN | disclosed |
| US-20200332441-A1 | MOLECULES FOR VERIFYING OLIGONUCLEOTIDE DIRECTED COMBINATORIAL SYNTHESIS AND METHODS OF MAKING AND USING THE SAME | INSITRO, INC. | 2020-10-22 | — | — | US | disclosed |
| US-10787442-B2 | Modulators of indoleamine 2,3-dioxygenase | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-09-29 | — | — | US | disclosed |
| US-10787442-B2 | Modulators of indoleamine 2,3-dioxygenase | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-09-29 | — | — | US | disclosed |
| EP-3372584-B1 | PROCESS FOR THE PREPARATION OF A DIARYLTHIOHYDANTOIN COMPOUND | ARAGON PHARMACEUTICALS INC (US) | 2020-09-23 | — | — | EP | disclosed |
| US-20200291010-A1 | HETEROAROMATIC MDOULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA | LEO PHARMA A/S | 2020-09-17 | — | — | US | disclosed |
| EP-3484880-B1 | HETEROAROMATIC MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA | LEO PHARMA AS (DK) | 2020-09-02 | — | — | EP | disclosed |
| US-10760052-B2 | Method of inhibiting tau phosphorylation | Cassava Science, Inc. (US) | 2020-09-01 | — | — | US | disclosed |
| EP-3054956-B1 | METHOD FOR INHIBITING GROWTH OF CANCER CELLS | PAIN THERAPEUTICS INC (US) | 2020-08-26 | — | — | EP | disclosed |
| US-20200263163-A1 | MULTINOMIAL ENCODING FOR OLIGONUCLEOTIDE-DIRECTED COMBINATORIAL CHEMISTRY | HAYSTACK SCIENCES CORPORATION (US) | 2020-08-20 | — | — | US | disclosed |
| EP-3688156-A1 | MULTINOMIAL ENCODING FOR OLIGONUCLEOTIDE-DIRECTED COMBINATORIAL CHEMISTRY | Haystack Sciences Corporation (US) | 2020-08-05 | — | — | EP | disclosed |
| US-10723714-B2 | Processes for the preparation of a diarylthiohydantoin compound | ARAGON PHARMACEUTICALS, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| EP-3353167-B1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2020-06-24 | — | — | EP | disclosed |
| EP-3353167-B1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2020-06-24 | — | — | EP | disclosed |
| US-10689367-B2 | Triazole pyridyl compounds as agonists of the APJ receptor | AMGEN INC. (US) | 2020-06-23 | — | — | US | disclosed |
| CN-111295444-A | Polynomial coding for oligonucleotide-directed combinatorial chemistry | 哈斯达克科学公司 | 2020-06-16 | — | — | CN | disclosed |
| US-10662181-B2 | Heteroaromatic modulators of the retinoid-related orphan receptor gamma | LEO PHARMA A/S (DK) | 2020-05-26 | — | — | US | disclosed |
| WO-2020099645-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2020-05-22 | — | — | WO | disclosed |
| CN-111065712-A | Isothiocyanatodiphenylacetylene derivatives | 默克专利股份有限公司 | 2020-04-24 | — | — | CN | disclosed |
| US-20200115374-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-04-16 | — | — | US | disclosed |
| US-20200115374-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-04-16 | — | — | US | disclosed |
| EP-3619340-A1 | MOLECULES FOR VERIFYING OLIGONUCLEOTIDE DIRECTED COMBINATORIAL SYNTHESIS AND METHODS OF MAKING AND USING THE SAME | Haystack Sciences Corporation (US) | 2020-03-11 | — | — | EP | disclosed |
| US-20200058881-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS FOR ORGANIC LIGHT EMITTING DEVICES | IDEMITSU KOSAN CO., LTD. (JP) | 2020-02-20 | — | — | US | disclosed |
| US-20200058881-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS FOR ORGANIC LIGHT EMITTING DEVICES | IDEMITSU KOSAN CO., LTD. (JP) | 2020-02-20 | — | — | US | disclosed |
| US-10472336-B2 | Modulators of indoleamine 2,3-dioxygenase | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-11-12 | — | — | US | disclosed |
| US-10472336-B2 | Modulators of indoleamine 2,3-dioxygenase | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-11-12 | — | — | US | disclosed |
| US-20190322652-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-10-24 | — | — | US | disclosed |
| US-20190322652-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-10-24 | — | — | US | disclosed |
| US-20190300507-A1 | TRIAZOLE PYRIDYL COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC. (US) | 2019-10-03 | — | — | US | disclosed |
| EP-1836174-B2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2019-10-02 | — | — | EP | disclosed |
| EP-3541803-A1 | TRIAZOLE PYRIDYL COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | Amgen Inc. (US) | 2019-09-25 | — | — | EP | disclosed |
| US-20190284156-A1 | Processes For The Preparation Of A Diarylthiohydantoin Compound | ARAGON PHARMACEUTICALS INC (US) | 2019-09-19 | — | — | US | disclosed |
| US-20190284177-A1 | HETEROAROMATIC MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA | LEO PHARMA A/S (DK) | 2019-09-19 | — | — | US | disclosed |
| US-20190271686-A1 | ALZHEIMER'S DISEASE ASSAY IN A LIVING PATIENT | PAIN THERAPEUTICS, INC. | 2019-09-05 | — | — | US | disclosed |
| US-10363239-B2 | Method for inhibiting growth of cancer cells | PAIN THERAPEUTICS (US) | 2019-07-30 | — | — | US | disclosed |
| US-10358427-B2 | Modulators of indoleamine 2,3-dioxygenase | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-07-23 | — | — | US | disclosed |
| US-10358427-B2 | Modulators of indoleamine 2,3-dioxygenase | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-07-23 | — | — | US | disclosed |
| EP-3074379-B1 | OPIOID AGONISTS AND USES THEREOF | NEKTAR THERAPEUTICS INDIA PVT LTD (IN) | 2019-06-26 | — | — | EP | disclosed |
| US-10316015-B2 | Processes for the preparation of a diarylthiohydantoin compound | ARAGON PHARMACEUTICALS, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-20190169607-A1 | OLIGONUCLEOTIDE DIRECTED AND RECORDED COMBINATORIAL SYNTHESIS OF ENCODED PROBE MOLECULES | INSITRO, INC. | 2019-06-06 | — | — | US | disclosed |
| EP-3484880-A1 | HETEROAROMATIC MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA | Leo Pharma A/S (DK) | 2019-05-22 | — | — | EP | disclosed |
| US-20190135775-A9 | PROCESSES FOR THE PREPARATION OF A DIARYLTHIOHYDANTOIN COMPOUND | ARAGON PHARMACEUTICALS, INC. | 2019-05-09 | — | — | US | disclosed |
| US-20190136184-A1 | METHOD OF INHIBITING TAU PHOSPHORYLATION | CASSAVA SCIENCES, INC. | 2019-05-09 | — | — | US | disclosed |
| EP-3472376-A1 | OLIGONUCLEOTIDE DIRECTED AND RECORDED COMBINATORIAL SYNTHESIS OF ENCODED PROBE MOLECULES | Watts, Richard Edward (US) | 2019-04-24 | — | — | EP | disclosed |
| WO-2019060856-A1 | MULTINOMIAL ENCODING FOR OLIGONUCLEOTIDE-DIRECTED COMBINATORIAL CHEMISTRY | HAYSTACK SCIENCES CORPORATION (US) | 2019-03-28 | — | — | WO | disclosed |
| US-10222368-B2 | Alzheimer's disease assay in a living patient | PAIN THERAPEUTICS, INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-20190040023-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-02-07 | — | — | US | disclosed |
| US-20190040023-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-02-07 | — | — | US | disclosed |
| CN-109312492-A | Combinatorial synthesis of oligonucleotide directed and recorded coded probe molecules | 哈斯达克科学公司 | 2019-02-05 | — | — | CN | disclosed |
| EP-3233803-B1 | PROCESS FOR THE PREPARATION OF A DIARYLTHIOHYDANTOIN COMPOUND | ARAGON PHARMACEUTICALS INC (US) | 2019-01-30 | — | — | EP | disclosed |
| EP-3233823-B1 | PROCESSES FOR THE PREPARATION OF A DIARYLTHIOHYDANTOIN COMPOUND | ARAGON PHARMACEUTICALS INC (US) | 2019-01-30 | — | — | EP | disclosed |
| US-20180360040-A1 | PESTICIDAL COMPOUNDS AND THEIR USES | SYNGENTA PARTICIPATIONS AG (CH) | 2018-12-20 | — | — | US | disclosed |
| US-20180362468-A1 | OPIOID AGONISTS AND USES THEREOF | NEKTAR THERAPEUTICS | 2018-12-20 | — | — | US | disclosed |
| WO-2018204420-A1 | MOLECULES FOR VERIFYING OLIGONUCLEOTIDE DIRECTED COMBINATORIAL SYNTHESIS AND METHODS OF MAKING AND USING THE SAME | HAYSTACK SCIENCES CORPORATION (US) | 2018-11-08 | — | — | WO | disclosed |
| US-20180290988-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-10-11 | — | — | US | disclosed |
| EP-3383178-A1 | PESTICIDAL COMPOUNDS AND THEIR USES | Syngenta Participations AG (CH) | 2018-10-10 | — | — | EP | disclosed |
| US-10081602-B2 | Opioid agonists and uses thereof | NEKTAR THERAPEUTICS (US) | 2018-09-25 | — | — | US | disclosed |
| EP-3372585-A1 | PROCESS FOR THE PREPARATION OF A DIARYLTHIOHYDANTOIN COMPOUND | Aragon Pharmaceuticals, Inc. (US) | 2018-09-12 | — | — | EP | disclosed |
| EP-3372586-A1 | PROCESS FOR THE PREPARATION OF A DIARYLTHIOHYDANTOIN COMPOUND | Aragon Pharmaceuticals, Inc. (US) | 2018-09-12 | — | — | EP | disclosed |
| EP-3372584-A1 | PROCESS FOR THE PREPARATION OF A DIARYLTHIOHYDANTOIN COMPOUND | Aragon Pharmaceuticals, Inc. (US) | 2018-09-12 | — | — | EP | disclosed |
| EP-2872899-B1 | ALZHEIMER'S DISEASE ASSAY IN A LIVING PATIENT | PAIN THERAPEUTICS INC (US) | 2018-07-11 | — | — | EP | disclosed |
| US-10017736-B2 | Method of inhibiting tau phosphorylation | PAIN THERAPEUTICS, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-10017736-B2 | Method of inhibiting tau phosphorylation | PAIN THERAPEUTICS, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| WO-2018124313-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS FOR ORGANIC LIGHT EMITTING DEVICES | IDEMITSU KOSAN CO., LTD. (JP) | 2018-07-05 | — | — | WO | disclosed |
| WO-2018116107-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018116108-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018093580-A1 | TRIAZOLE PYRIDYL COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC. (US) | 2018-05-24 | — | — | WO | disclosed |
| WO-2018011201-A1 | HETEROAROMATIC MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA | LEO PHARMA A/S (DK) | 2018-01-18 | — | — | WO | disclosed |
| US-20180002309-A1 | PROCESSES FOR THE PREPARATION OF A DIARYLTHIOHYDANTOIN COMPOUND | ARAGON PHARMACEUTICALS INC (US) | 2018-01-04 | — | — | US | disclosed |
| EP-3233823-A1 | PROCESSES FOR THE PREPARATION OF A DIARYLTHIOHYDANTOIN COMPOUND | Aragon Pharmaceuticals, Inc. (US) | 2017-10-25 | — | — | EP | disclosed |
| EP-3233803-A2 | PROCESS FOR THE PREPARATION OF A DIARYLTHIOHYDANTOIN COMPOUND | Aragon Pharmaceuticals, Inc. (US) | 2017-10-25 | — | — | EP | disclosed |
| US-20170253565-A1 | OPIOID AGONISTS AND USES THEREOF | NEKTAR THERAPEUTICS | 2017-09-07 | — | — | US | disclosed |
| US-20170182193-A1 | THERAPEUTIC CONJUGATES WITH SULFATED DENDRIMERS FOR INTRACELLULAR TARGETING | ICD-THERAPEUTICS GMBH (DE) | 2017-06-29 | — | — | US | disclosed |
| US-9688655-B2 | Process for the preparation of a diarylthiohydantoin compound | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-27 | — | — | US | disclosed |
| US-9688638-B2 | Opioid agonists and uses thereof | NEKTAR THERAPEUTICS (US) | 2017-06-27 | — | — | US | disclosed |
| WO-2017093409-A1 | PESTICIDAL COMPOUNDS AND THEIR USES | SYNGENTA PARTICIPATIONS AG (CH) | 2017-06-08 | — | — | WO | disclosed |
| WO-2017093409-A1 | PESTICIDAL COMPOUNDS AND THEIR USES | SYNGENTA PARTICIPATIONS AG (CH) | 2017-06-08 | — | — | WO | disclosed |
| WO-2017051354-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-03-30 | — | — | WO | disclosed |
| WO-2017051353-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-03-30 | — | — | WO | disclosed |
| EP-3145984-A1 | THERAPEUTIC CONJUGATES WITH SULFATED DENDRIMERS FOR INTRACELLULAR TARGETING | IC Discovery GmbH (DE) | 2017-03-29 | — | — | EP | disclosed |
| EP-2411359-B1 | NOVEL OLIGOFUNCTIONAL PHOTOINITIATORS | BASF SE (DE) | 2017-02-01 | — | — | EP | disclosed |
| US-20170022167-A1 | OPIOID AGONISTS AND USES THEREOF | NEKTAR THERAPEUTICS | 2017-01-26 | — | — | US | disclosed |
| US-9500640-B2 | Alzheimer's disease assay in a living patient | PAIN THERAPEUTICS, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-9500640-B2 | Alzheimer's disease assay in a living patient | PAIN THERAPEUTICS, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-9487517-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-11-08 | — | — | US | disclosed |
| US-9433604-B2 | Method for inhibiting growth of cancer cells | PAIN THERAPEUTICS INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-9433604-B2 | Method for inhibiting growth of cancer cells | PAIN THERAPEUTICS INC. (US) | 2016-09-06 | — | — | US | disclosed |
| WO-2016100645-A1 | PROCESSES FOR THE PREPARATION OF A DIARYLTHIOHYDANTOIN COMPOUND | ARAGON PHARMACEUTICALS, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016100652-A2 | PROCESS FOR THE PREPARATION OF A DIARYLTHIOHYDANTOIN COMPOUND | ARAGON PHARMACEUTICALS, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| US-20160176844-A1 | PROCESSES FOR THE PREPARATION OF A DIARYLTHIOHYDANTOIN COMPOUND | JANSSEN PHARMACEUTICA NV (BE) | 2016-06-23 | — | — | US | disclosed |
| US-20160176845-A1 | PROCESS FOR THE PREPARATION OF A DIARYLTHIOHYDANTOIN COMPOUND | JANSSEN PHARMACEUTICA NV (BE) | 2016-06-23 | — | — | US | disclosed |
| US-9354223-B2 | Alzheimer's disease assay in a living patient | PAIN THERAPEUTICS INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-9354223-B2 | Alzheimer's disease assay in a living patient | PAIN THERAPEUTICS INC. (US) | 2016-05-31 | — | — | US | disclosed |
| EP-2753607-B1 | BICYCLO[6.1.0]NON-4-YNE REAGENTS FOR CHEMICAL MODIFICATION OF OLIGONUCLEOTIDES | BERRY AND ASSOCIATES INC (US) | 2016-04-13 | — | — | EP | disclosed |
| US-9273134-B2 | Inhibitors of receptor tyrosine kinases and methods of use thereof | YALE UNIVERSITY (US) | 2016-03-01 | — | — | US | disclosed |
| US-9273134-B2 | Inhibitors of receptor tyrosine kinases and methods of use thereof | YALE UNIVERSITY (US) | 2016-03-01 | — | — | US | disclosed |
| US-20160016956-A1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-01-21 | — | — | US | disclosed |
| WO-2015177279-A1 | THERAPEUTIC CONJUGATES WITH SULFATED DENDRIMERS FOR INTRACELLULAR TARGETING | IC DISCOVERY GMBH (DE) | 2015-11-26 | — | — | WO | disclosed |
| US-20150329522-A1 | MELANOCORTIN RECEPTOR ANTAGONIST COMPOUNDS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2015-11-19 | — | — | US | disclosed |
| US-9174984-B2 | Chemical compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2015-11-03 | — | — | US | disclosed |
| US-9174984-B2 | Chemical compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2015-11-03 | — | — | US | disclosed |
| US-9174984-B2 | Chemical compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2015-11-03 | — | — | US | disclosed |
| US-9169254-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-10-27 | — | — | US | disclosed |
| US-9133228-B2 | Guanidinyl-substituted polyamides useful for treating human papilloma virus | NANOVIR LLC (US) | 2015-09-15 | — | — | US | disclosed |
| EP-2649071-B1 | Imidazo(4,5-b)pyridine-6-carboxamides as anti-inflammatory agents | OREXO AB (SE) | 2015-07-08 | — | — | EP | disclosed |
| US-20150148318-A1 | METHOD FOR INHIBITING GROWTH OF CANCER CELLS | PAIN THERAPEUTICS, INC. | 2015-05-28 | — | — | US | disclosed |
| US-20150148318-A1 | METHOD FOR INHIBITING GROWTH OF CANCER CELLS | PAIN THERAPEUTICS, INC. | 2015-05-28 | — | — | US | disclosed |
| WO-2015054027-A1 | METHOD FOR INHIBITING GROWTH OF CANCER CELLS | PAIN THERAPEUTICS, INC. (US) | 2015-04-16 | — | — | WO | disclosed |
| US-8962846-B2 | Melanocortin receptor antagonist compounds, process for preparing them and use thereof in human medicine and cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2015-02-24 | — | — | US | disclosed |
| US-8962637-B2 | Bicyclic compounds and their uses as dual c-SRC/JAK inhibitors | DEBIOPHARM S.A. (CH) | 2015-02-24 | — | — | US | disclosed |
| US-8962637-B2 | Bicyclic compounds and their uses as dual c-SRC/JAK inhibitors | DEBIOPHARM S.A. (CH) | 2015-02-24 | — | — | US | disclosed |
| US-8962637-B2 | Bicyclic compounds and their uses as dual c-SRC/JAK inhibitors | DEBIOPHARM S.A. (CH) | 2015-02-24 | — | — | US | disclosed |
| US-20150011513-A1 | ALKYNE-, AZIDE- AND TRIAZOLE-CONTAINING FLAVONOIDS AS MODULATORS FOR MULTIDRUG RESISTANCE IN CANCERS | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2015-01-08 | — | — | US | disclosed |
| US-8921405-B2 | Compounds | OREXO AB (SE) | 2014-12-30 | — | — | US | disclosed |
| US-8921405-B2 | Compounds | OREXO AB (SE) | 2014-12-30 | — | — | US | disclosed |
| US-8921405-B2 | Compounds | OREXO AB (SE) | 2014-12-30 | — | — | US | disclosed |
| US-8916599-B2 | 1H-benz imidazole-5-carboxamides as anti-inflammatory agents | OREXO AB (SE) | 2014-12-23 | — | — | US | disclosed |
| US-20140357599-A1 | NOVEL UREA AND THIOUREA DERIVATIVES | ONXEO DK, BRANCH OF ONXEO S.A., FRANCE (DK) | 2014-12-04 | — | — | US | disclosed |
| US-8877968-B2 | Melanocortin receptor modulators, process for preparing them and use there in human medicine and cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-11-04 | — | — | US | disclosed |
| EP-2403852-B1 | 2-AMINOBENZIMIDAZOLE-5-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM INT (DE) | 2014-10-29 | — | — | EP | disclosed |
| EP-2403852-B1 | 2-AMINOBENZIMIDAZOLE-5-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM INT (DE) | 2014-10-29 | — | — | EP | disclosed |
| EP-2649052-B1 | 2-AMINOBENZIMIDAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF INFLAMMATION | BOEHRINGER INGELHEIM INT (DE) | 2014-10-22 | — | — | EP | disclosed |
| EP-2649052-B1 | 2-AMINOBENZIMIDAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF INFLAMMATION | BOEHRINGER INGELHEIM INT (DE) | 2014-10-22 | — | — | EP | disclosed |
| US-8859599-B2 | Androgen receptor modulating compounds, preparation and uses thereof | CNR—Consiglio Nazionale Delle Ricerche (IT) | 2014-10-14 | — | — | US | disclosed |
| EP-2606036-B1 | 2-ANILINOBENZIMIDAZOLE-6-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM INT (DE) | 2014-10-08 | — | — | EP | disclosed |
| US-20140296204-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2014-10-02 | — | — | US | disclosed |
| US-20140296204-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2014-10-02 | — | — | US | disclosed |
| US-20140296204-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2014-10-02 | — | — | US | disclosed |
| US-8809346-B2 | ANT-ligands molecules and biological applications | UNIVERSITE DE VERSAILLES-SAINT-QUENTIN-EN-YVELINES (FR) | 2014-08-19 | — | — | US | disclosed |
| US-8809346-B2 | ANT-ligands molecules and biological applications | UNIVERSITE DE VERSAILLES-SAINT-QUENTIN-EN-YVELINES (FR) | 2014-08-19 | — | — | US | disclosed |
| EP-2751096-A2 | GUANIDINYL-SUBSTITUTED POLYAMIDES USEFUL FOR TREATING HUMAN PAPILLOMA VIRUS | Nanovir, LLC (US) | 2014-07-09 | — | — | EP | disclosed |
| US-8759537-B2 | 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-24 | — | — | US | disclosed |
| US-8759532-B2 | Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors | AMGEN INC. (US) | 2014-06-24 | — | — | US | disclosed |
| EP-2352728-B1 | MELANOCORTIN RECEPTOR MODULATORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS | GALDERMA RES & DEV (FR) | 2014-05-21 | — | — | EP | disclosed |
| EP-2352729-B1 | MELANOCORTIN RECEPTOR ANTAGONIST COMPOUNDS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS | GALDERMA RES & DEV (FR) | 2014-05-14 | — | — | EP | disclosed |
| EP-2536722-B1 | BICYCLIC COMPOUNDS AND THEIR USES AS DUAL C-SRC / JAK INHIBITORS | DEBIOPHARM SA (CH) | 2014-04-16 | — | — | EP | disclosed |
| EP-2536722-B1 | BICYCLIC COMPOUNDS AND THEIR USES AS DUAL C-SRC / JAK INHIBITORS | DEBIOPHARM SA (CH) | 2014-04-16 | — | — | EP | disclosed |
| US-8674113-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-03-18 | — | — | US | disclosed |
| US-20140018341-A1 | METHOD OF INHIBITING TAU PHOSPHORYLATION | CASSAVA SCIENCES, INC. | 2014-01-16 | — | — | US | disclosed |
| US-20140018341-A1 | METHOD OF INHIBITING TAU PHOSPHORYLATION | CASSAVA SCIENCES, INC. | 2014-01-16 | — | — | US | disclosed |
| US-20140017699-A1 | ALZHEIMER'S DISEASE ASSAY IN A LIVING PATIENT | CASSAVA SCIENCES, INC. | 2014-01-16 | — | — | US | disclosed |
| US-20140017698-A1 | ALZHEIMER'S DISEASE ASSAY IN A LIVING PATIENT | WANG HOAU-YAN (US) | 2014-01-16 | — | — | US | disclosed |
| US-20140017699-A1 | ALZHEIMER'S DISEASE ASSAY IN A LIVING PATIENT | CASSAVA SCIENCES, INC. | 2014-01-16 | — | — | US | disclosed |
| US-20140017698-A1 | ALZHEIMER'S DISEASE ASSAY IN A LIVING PATIENT | WANG HOAU-YAN (US) | 2014-01-16 | — | — | US | disclosed |
| EP-2298754-B9 | Preparation of taxane derivatives | INDENA SPA (IT) | 2013-12-18 | — | — | EP | disclosed |
| US-8586604-B2 | Inhibitors of the microsomal prostaglandin E2 synthase-1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-19 | — | — | US | disclosed |
| US-20130303571-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-14 | — | — | US | disclosed |
| US-20130303571-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-14 | — | — | US | disclosed |
| US-20130303571-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-14 | — | — | US | disclosed |
| US-8580968-B2 | Benzothiazole and benzooxazole derivatives and methods of use | ABBVIE INC. (US) | 2013-11-12 | — | — | US | disclosed |
| EP-2649052-A1 | 2 -AMINOBENZ IMIDAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF INFLAMMATION | Boehringer Ingelheim International GmbH (DE) | 2013-10-16 | — | — | EP | disclosed |
| EP-2298754-B1 | Preparation of taxane derivatives | INDENA SPA (IT) | 2013-08-07 | — | — | EP | disclosed |
| EP-2264019-B1 | Intermediates for the preparation of taxane derivatives | INDENA SPA (IT) | 2013-07-24 | — | — | EP | disclosed |
| US-8486968-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-16 | — | — | US | disclosed |
| US-8476473-B2 | Compound, method for preparing the compound and resist composition containing the compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-07-02 | — | — | US | disclosed |
| US-8466186-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-18 | — | — | US | disclosed |
| US-8466186-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-18 | — | — | US | disclosed |
| US-8466186-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-18 | — | — | US | disclosed |
| US-20130143895-A1 | BICYCLIC COMPOUNDS AND THEIR USES AS DUAL C-SRC / JAK INHIBITORS | DEBIOPHARM S.A. (CH) | 2013-06-06 | — | — | US | disclosed |
| US-20130143895-A1 | BICYCLIC COMPOUNDS AND THEIR USES AS DUAL C-SRC / JAK INHIBITORS | DEBIOPHARM S.A. (CH) | 2013-06-06 | — | — | US | disclosed |
| US-20130143895-A1 | BICYCLIC COMPOUNDS AND THEIR USES AS DUAL C-SRC / JAK INHIBITORS | DEBIOPHARM S.A. (CH) | 2013-06-06 | — | — | US | disclosed |
| US-20130142739-A1 | PROCESS FOR THE SYNTHESIS OF ISOTHIOCYANATES AND DERIVATIVES THEREOF AND USES OF SAME | AURIGA INTERNATIONAL (BE) | 2013-06-06 | — | — | US | disclosed |
| EP-2595953-A1 | PROCESS FOR THE SYNTHESIS OF ISOTHIOCYANATES AND DERIVATIVES THEREOF AND USES OF SAME | Auriga International (BE) | 2013-05-29 | — | — | EP | disclosed |
| US-8440679-B2 | Bicyclic compounds and their uses as dual c-SRC / JAK inhibitors | DEBIOPHARM S.A. (CH) | 2013-05-14 | — | — | US | disclosed |
| US-8440679-B2 | Bicyclic compounds and their uses as dual c-SRC / JAK inhibitors | DEBIOPHARM S.A. (CH) | 2013-05-14 | — | — | US | disclosed |
| US-8440679-B2 | Bicyclic compounds and their uses as dual c-SRC / JAK inhibitors | DEBIOPHARM S.A. (CH) | 2013-05-14 | — | — | US | disclosed |
| US-20130116203-A1 | ISOTHIOCYNATES AND GLUCOSINOLATE COMPOUNDS AND ANTI-TUMOR COMPOSITIONS CONTAINING SAME | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2013-05-09 | — | — | US | disclosed |
| WO-2013062945-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-05-02 | — | — | WO | disclosed |
| EP-2364306-B1 | Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors | AMGEN INC (US) | 2013-04-24 | — | — | EP | disclosed |
| WO-2013055825-A2 | GUANIDINYL-SUBSTITUTED POLYAMIDES USEFUL FOR TREATING HUMAN PAPILLOMA VIRUS | NANOVIR, LLC (US) | 2013-04-18 | — | — | WO | disclosed |
| EP-1637527-B1 | CANNABINOID RECEPTOR MODULATOR | TAKEDA PHARMACEUTICAL (JP) | 2013-04-17 | — | — | EP | disclosed |
| US-20130090362-A1 | GUANIDINYL-SUBSTITUTED POLYAMIDES USEFUL FOR TREATING HUMAN PAPILLOMA VIRUS | NANOVIR, LLC (US) | 2013-04-11 | — | — | US | disclosed |
| US-8410028-B2 | Methods for synthesis of encoded libraries | GLAXOSMITHKLINE LLC (US) | 2013-04-02 | — | — | US | disclosed |
| US-8410028-B2 | Methods for synthesis of encoded libraries | GLAXOSMITHKLINE LLC (US) | 2013-04-02 | — | — | US | disclosed |
| US-20130079325-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | ALLEN JENNIFER R (US) | 2013-03-28 | — | — | US | disclosed |
| US-20130079325-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | ALLEN JENNIFER R (US) | 2013-03-28 | — | — | US | disclosed |
| US-20130079325-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | ALLEN JENNIFER R (US) | 2013-03-28 | — | — | US | disclosed |
| US-20130071397-A1 | INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) RECEPTORS AND METHODS OF USE THEREOF | YALE UNIVERSITY (US) | 2013-03-21 | — | — | US | disclosed |
| US-20130071397-A1 | INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) RECEPTORS AND METHODS OF USE THEREOF | YALE UNIVERSITY (US) | 2013-03-21 | — | — | US | disclosed |
| US-20130066063-A1 | BICYCLO[6.1.0]NON-4-YNE REGENTS FOR CHEMICAL MODIFICATION OF OLIGONUCLEOTIDES | BERRY AND ASSOCIATES, INC. | 2013-03-14 | — | — | US | disclosed |
| WO-2013036748-A1 | BICYCLO[6.1.0]NON-4-YNE REAGENTS FOR CHEMICAL MODIFICATION OF OLIGONUCLEOTIDES | BERRY, LANA, L. (US) | 2013-03-14 | — | — | WO | disclosed |
| EP-1836174-B1 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2013-02-27 | — | — | EP | disclosed |
| US-8372807-B2 | Methods of modulating uric acid levels | ARDEA BIOSCIENCES, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-20130012518-A1 | BICYCLIC COMPOUNDS AND THEIR USES AS DUAL C-SRC / JAK INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LTD. (IN) | 2013-01-10 | — | — | US | disclosed |
| US-20130012518-A1 | BICYCLIC COMPOUNDS AND THEIR USES AS DUAL C-SRC / JAK INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LTD. (IN) | 2013-01-10 | — | — | US | disclosed |
| US-20130012518-A1 | BICYCLIC COMPOUNDS AND THEIR USES AS DUAL C-SRC / JAK INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LTD. (IN) | 2013-01-10 | — | — | US | disclosed |
| US-20120328599-A1 | INHIBITORS OF RECEPTOR TYROSINE KINASES (RTK) AND METHODS OF USE THEREOF | YALE UNIVERSITY (US) | 2012-12-27 | — | — | US | disclosed |
| US-20120328599-A1 | INHIBITORS OF RECEPTOR TYROSINE KINASES (RTK) AND METHODS OF USE THEREOF | YALE UNIVERSITY (US) | 2012-12-27 | — | — | US | disclosed |
| EP-2536722-A1 | BICYCLIC COMPOUNDS AND THEIR USES AS DUAL C-SRC / JAK INHIBITORS | Debiopharm S.A. (CH) | 2012-12-26 | — | — | EP | disclosed |
| US-20120309755-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-06 | — | — | US | disclosed |
| US-20120309738-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-06 | — | — | US | disclosed |
| US-20120309738-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-06 | — | — | US | disclosed |
| US-20120309738-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-06 | — | — | US | disclosed |
| US-8318718-B2 | Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors | AMGEN INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318718-B2 | Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors | AMGEN INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318718-B2 | Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors | AMGEN INC. (US) | 2012-11-27 | — | — | US | disclosed |
| EP-2077264-B1 | Taxane derivatives and a process for the preparation thereof | INDENA SPA (IT) | 2012-11-14 | — | — | EP | disclosed |
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-10-25 | — | — | US | disclosed |
| US-20120264755-A1 | PYRIDINYL DERIVATIVES AS INHIBITORS OF ENZYME NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE | TopoTarget (DE) | 2012-10-18 | — | — | US | disclosed |
| US-20120214786-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-23 | — | — | US | disclosed |
| US-20120208839-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-16 | — | — | US | disclosed |
| US-20120196897-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-02 | — | — | US | disclosed |
| US-20120196897-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-02 | — | — | US | disclosed |
| US-20120196897-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-02 | — | — | US | disclosed |
| US-20120164070-A1 | BENZOTHIAZOLE AND BENZOOXAZOLE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120149676-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-14 | — | — | US | disclosed |
| WO-2012076672-A1 | 2 -AMINOBENZ IMIDAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF INFLAMMATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-14 | — | — | WO | disclosed |
| WO-2012076672-A1 | 2 -AMINOBENZ IMIDAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF INFLAMMATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-14 | — | — | WO | disclosed |
| US-8198458-B2 | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-12 | — | — | US | disclosed |
| US-20120135929-A1 | Methods Of Modulating Uric Acid Levels | ARDEA BIOSCIENCES INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-8163768-B2 | 4-(4-Hydroxy-3-methyl-phenyl)-2,4,6,7,8,9-hexahydro-pyrazolo[3,4-b]-1,7-naphthyridin-5-one; inhibiting Aurora kinase; inhibiting the proliferation of tumor cells; cancer, psoriasis, leukaemia and lupus | AVENTIS PHARMA S.A.. (FR) | 2012-04-24 | — | — | US | disclosed |
| EP-2440527-A1 | PYRIDINYL DERIVATIVES AS INHIBITORS OF ENZYME NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE | Topo Target A/S (DK) | 2012-04-18 | — | — | EP | disclosed |
| US-8153813-B2 | Benzothiazole and benzooxazole derivatives and methods of use | ABBOTT LABORATORIES (US) | 2012-04-10 | — | — | US | disclosed |
| EP-2432468-A2 | METHODS OF MODULATING URIC ACID LEVELS | Ardea Biosciences, Inc. (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20120071329-A1 | METHODS FOR IDENTIFYING COMPOUNDS OF INTEREST USING ENCODED LIBRARIES | GLAXOSMITHKLINE LLC (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120071329-A1 | METHODS FOR IDENTIFYING COMPOUNDS OF INTEREST USING ENCODED LIBRARIES | GLAXOSMITHKLINE LLC (US) | 2012-03-22 | — | — | US | disclosed |
| WO-2012010644-A1 | PROCESS FOR THE SYNTHESIS OF ISOTHIOCYANATES AND DERIVATIVES THEREOF AND USES OF SAME | AURIGA INTERNATIONAL (BE) | 2012-01-26 | — | — | WO | disclosed |
| EP-2403852-A1 | 3H-IMIDAZO [4, 5 -C]PYRIDINE- 6 -CARBOXAMIDES AS ANTI- INFLAMMATORY AGENTS | Boehringer Ingelheim International GmbH (DE) | 2012-01-11 | — | — | EP | disclosed |
| US-20110311538-A1 | INHIBITORS OF RECEPTOR TYROSINE KINASES AND METHODS OF USE THEREOF | YALE UNIVERSITY (US) | 2011-12-22 | — | — | US | disclosed |
| US-20110311538-A1 | INHIBITORS OF RECEPTOR TYROSINE KINASES AND METHODS OF USE THEREOF | YALE UNIVERSITY (US) | 2011-12-22 | — | — | US | disclosed |
| US-20110312935-A1 | 1H-Benz Imidazole-5-Carboxamides As Anti-Inflammatory Agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| US-8062756-B2 | Stepwise growth of oligomeric redox-active molecules on a surface without the use of protecting groups | The Regents oft the University of California (US) | 2011-11-22 | — | — | US | disclosed |
| US-20110281913-A1 | MELANOCORTIN RECEPTOR ANTAGONIST COMPOUNDS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-11-17 | — | — | US | disclosed |
| WO-2011140295-A2 | MODULATORS OF NOTCH RECEPTOR SIGNALING AND METHODS OF USE THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2011-11-10 | — | — | WO | disclosed |
| US-20110275657-A1 | MELANOCORTIN RECEPTOR MODULATORS, PROCESS FOR PREPARING THEM AND USE THERE IN HUMAN MEDICINE AND COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-11-10 | — | — | US | disclosed |
| US-20110275829-A1 | Androgen receptor modulating compounds, preparation and uses thereof | CNR - CONSIGLIO NAZIONALE DELLE RICERCHE (IT) | 2011-11-10 | — | — | US | disclosed |
| US-20110251089-A1 | METHODS FOR SYNTHESIS OF ENCODED LIBRARIES | GLAXOSMITHKLINE (US) | 2011-10-13 | — | — | US | disclosed |
| US-20110251089-A1 | METHODS FOR SYNTHESIS OF ENCODED LIBRARIES | GLAXOSMITHKLINE (US) | 2011-10-13 | — | — | US | disclosed |
| WO-2011122815-A2 | NOVEL QUINOXALINE DERIVATIVES | DONG-A PHARM.CO.,LTD. (KR) | 2011-10-06 | — | — | WO | disclosed |
| WO-2011121055-A1 | PYRIDINYL DERIVATIVES COMPRISING A CYANOGUANIDINE OR SQUARIC ACID MOIETY | TOPOTARGET A/S (DK) | 2011-10-06 | — | — | WO | disclosed |
| EP-1885704-B1 | ANTAGONISTS OF THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USES THEREOF | ABBOTT LAB (US) | 2011-09-28 | — | — | EP | disclosed |
| EP-2364306-A1 | Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors | Amgen Inc. (US) | 2011-09-14 | — | — | EP | disclosed |
| WO-2011101806-A1 | BICYCLIC COMPOUNDS AND THEIR USES AS DUAL C-SRC / JAK INHIBITORS | DEBIOPHARM S.A. (CH) | 2011-08-25 | — | — | WO | disclosed |
| WO-2011101806-A1 | BICYCLIC COMPOUNDS AND THEIR USES AS DUAL C-SRC / JAK INHIBITORS | DEBIOPHARM S.A. (CH) | 2011-08-25 | — | — | WO | disclosed |
| EP-1910366-B1 | 1,4-DIHYDROPYRIDINE-FUSED HETEROCYCLES, PROCESS FOR PREPARING THE SAME, USE AND COMPOSITIONS CONTAINING THEM | AVENTIS PHARMA SA (FR) | 2011-08-24 | — | — | EP | disclosed |
| EP-2352728-A1 | MELANOCORTIN RECEPTOR MODULATORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS | Galderma Research & Development (FR) | 2011-08-10 | — | — | EP | disclosed |
| EP-2352729-A1 | MELANOCORTIN RECEPTOR ANTAGONIST COMPOUNDS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS | Galderma Research & Development (FR) | 2011-08-10 | — | — | EP | disclosed |
| US-20110189618-A1 | RESIST PROCESSING METHOD | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-08-04 | — | — | US | disclosed |
| US-7989395-B2 | Methods for identifying compounds of interest using encoded libraries | GLAXOSMITHKLINE LLC (US) | 2011-08-02 | — | — | US | disclosed |
| US-7989395-B2 | Methods for identifying compounds of interest using encoded libraries | GLAXOSMITHKLINE LLC (US) | 2011-08-02 | — | — | US | disclosed |
| WO-2011090648-A2 | INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) RECEPTORS AND METHODS OF USE THEREOF | YALE UNIVERSITY (US) | 2011-07-28 | — | — | WO | disclosed |
| WO-2011088196-A2 | INHIBITORS OF RECEPTOR TYROSINE KINASES (RTK) AND METHODS OF USE THEREOF | YALE UNIVERSITY (US) | 2011-07-21 | — | — | WO | disclosed |
| US-7972994-B2 | Methods for synthesis of encoded libraries | GLAXOSMITHKLINE LLC (US) | 2011-07-05 | — | — | US | disclosed |
| US-7972994-B2 | Methods for synthesis of encoded libraries | GLAXOSMITHKLINE LLC (US) | 2011-07-05 | — | — | US | disclosed |
| US-20110144057-A1 | ANTAGONISTS OF THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USE THEREOF | ABBOTT LABORATORIES (US) | 2011-06-16 | — | — | US | disclosed |
| US-7928119-B2 | Use of EP4 receptor ligands in the treatment of IL-6 involved diseases | PFIZER INC. (US) | 2011-04-19 | — | — | US | disclosed |
| US-20110086865-A1 | ANT-LIGANDS MOLECULES AND BIOLOGICAL APPLICATIONS | MITOLOGICS (FR) | 2011-04-14 | — | — | US | disclosed |
| US-20110086865-A1 | ANT-LIGANDS MOLECULES AND BIOLOGICAL APPLICATIONS | MITOLOGICS (FR) | 2011-04-14 | — | — | US | disclosed |
| EP-2298754-A1 | Preparation of taxane derivatives | Indena S.p.A. (IT) | 2011-03-23 | — | — | EP | disclosed |
| US-7902236-B2 | Antagonists of the vanilloid receptor subtype 1 (VR1) and use thereof | ABBOTT LABORATORIES (US) | 2011-03-08 | — | — | US | disclosed |
| EP-2281820-A2 | Taxane derivatives and a process for the preparation thereof | Indena S.p.A. (IT) | 2011-02-09 | — | — | EP | disclosed |
| US-7868177-B2 | Multi-cyclic compounds and method of use | AMGEN INC. (US) | 2011-01-11 | — | — | US | disclosed |
| EP-2264019-A1 | Intermediates fot the preparation of taxane derivatives | Indena S.p.A. (IT) | 2010-12-22 | — | — | EP | disclosed |
| WO-2010142735-A1 | PYRIDINYL DERIVATIVES AS INHIBITORS OF ENZYME NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE | TOPOTARGET A/S (DK) | 2010-12-16 | — | — | WO | disclosed |
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2010-12-16 | — | — | US | disclosed |
| WO-2010135536-A2 | METHODS OF MODULATING URIC ACID LEVELS | ARDEA BIOSCIENCES, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
| EP-2237779-A1 | BENZOTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND METHODS OF USE | Abbott Laboratories (US) | 2010-10-13 | — | — | EP | disclosed |
| US-20100256188-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-07 | — | — | US | disclosed |
| US-20100256188-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-07 | — | — | US | disclosed |
| US-20100256188-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-07 | — | — | US | disclosed |
| US-20100240743-A1 | CANNABINOID RECEPTOR MODULATOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-23 | — | — | US | disclosed |
| US-7795283-B2 | Oxadiazole derivative as DGAT inhibitors | ASTRAZENECA AB (SE) | 2010-09-14 | — | — | US | disclosed |
| WO-2010100249-A1 | 3H-IMIDAZO [4, 5 -C] PYRIDINE- 6 -CARBOXAMIDES AS ANTI- INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-10 | — | — | WO | disclosed |
| WO-2010100249-A1 | 3H-IMIDAZO [4, 5 -C] PYRIDINE- 6 -CARBOXAMIDES AS ANTI- INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-10 | — | — | WO | disclosed |
| EP-1994030-B1 | MULTI-CYCLIC COMPOUNDS AND METHOD OF USE | AMGEN INC (US) | 2010-08-25 | — | — | EP | disclosed |
| US-20100168091-A1 | Imidazole Amines As Inhibitors Of Beta-secretase | WYETH LLC (US) | 2010-07-01 | — | — | US | disclosed |
| US-20100168091-A1 | Imidazole Amines As Inhibitors Of Beta-secretase | WYETH LLC (US) | 2010-07-01 | — | — | US | disclosed |
| US-20100168091-A1 | Imidazole Amines As Inhibitors Of Beta-secretase | WYETH LLC (US) | 2010-07-01 | — | — | US | disclosed |
| US-20100125062-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMEN INC. (US) | 2010-05-20 | — | — | US | disclosed |
| US-20100125062-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMEN INC. (US) | 2010-05-20 | — | — | US | disclosed |
| US-20100125062-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMEN INC. (US) | 2010-05-20 | — | — | US | disclosed |
| WO-2010057126-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010057126-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010052255-A1 | MELANOCORTIN RECEPTOR MODULATORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-05-14 | — | — | WO | disclosed |
| WO-2010052256-A1 | MELANOCORTIN RECEPTOR ANTAGONIST COMPOUNDS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-05-14 | — | — | WO | disclosed |
| US-20100105673-A1 | SUBSTITUTED AMINOFURANONES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-29 | — | — | US | disclosed |
| US-7700606-B2 | Imidazole amines as inhibitors of β-secretase | WYETH LLC (US) | 2010-04-20 | — | — | US | disclosed |
| US-7700606-B2 | Imidazole amines as inhibitors of β-secretase | WYETH LLC (US) | 2010-04-20 | — | — | US | disclosed |
| US-7700606-B2 | Imidazole amines as inhibitors of β-secretase | WYETH LLC (US) | 2010-04-20 | — | — | US | disclosed |
| US-20100055609-A1 | COMPOUND, METHOD FOR PREPARING THE COMPOUND AND RESIST COMPOSITION CONTAINING THE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-03-04 | — | — | US | disclosed |
| US-20100022527-A1 | BIPHENYL SUBSTITUTED SPIROTETRONIC ACIDS AND THEIR USE FOR THE TREATMENT OF RETROVIRAL DISEASES | AICURIS GMBH & CO. KG (DE) | 2010-01-28 | — | — | US | disclosed |
| US-20100010055-A1 | ANTAGONISTS OF THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USE THEREOF | ABBOTT LABORATORIES (US) | 2010-01-14 | — | — | US | disclosed |
| US-20090270391-A1 | THIENOPYRIDINE DERIVATIVE, OR QUINOLINE DERIVATIVE, OR QUINAZOLINE DERIVATIVE, HAVING c-MET AUTOPHOSPHORYLATION INHIBITING POTENCY | KIRIN PHARMA KABUSHIKI KAISHA (JP) | 2009-10-29 | — | — | US | disclosed |
| EP-1465880-B1 | 5-SULPHANYL-4H-1,2,4-TRIAZOLE DERIVATIVES AND THEIR USE TO TREAT DISORDERS ASSOCIATED WITH SOMATOSTATINE | IPSEN PHARMA (FR) | 2009-08-05 | — | — | EP | disclosed |
| WO-2009086835-A1 | NOVEL CYANOGUANIDINES | TOPOTARGET A/S (DK) | 2009-07-16 | — | — | WO | disclosed |
| WO-2009085945-A1 | BENZOTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2009-07-09 | — | — | WO | disclosed |
| EP-2077264-A2 | Taxane derivatives and a process for the preparation thereof | INDENA S.p.A. (IT) | 2009-07-08 | — | — | EP | disclosed |
| US-20090163464-A1 | BENZOTHIAZOLE AND BENZOOXAZOLE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2009-06-25 | — | — | US | disclosed |
| US-20090143370-A1 | Non-nucleoside Reverse Transcriptase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-04 | — | — | US | disclosed |
| EP-2054414-A2 | IMIDAZOLE AMINES AS INHIBITORS OF BETA-SECRETASE | Wyeth (US) | 2009-05-06 | — | — | EP | disclosed |
| US-7517998-B2 | Benzothiazole or benzothiazine derivative of dipyrido(2,3;b:2',3'-e) diazepin-6-one; viricide against human t-cell leukemia/lymphoma virus | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2009-04-14 | — | — | US | disclosed |
| EP-2044072-A1 | AMINO-IMIDAZOLONES AND THEIR USE AS A MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT, ALZHEIMER DISEASE, NEURODEGENERATION AND DEMENTIA | AstraZeneca AB (SE) | 2009-04-08 | — | — | EP | disclosed |
| US-7507841-B2 | Carbamoylamino-substituted 2,3-dihydro-benzofurans, indoles and benzothiophenes, e.g., (+)-N-((3R)-3-(4-isopropylphenyl)-4,6,7-trimethyl-2,3-dihydro-1-benzofuran-5-yl)-3,3-dimethylbutanamide; cerebrovascular disorders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-03-24 | — | — | US | disclosed |
| EP-2035425-A1 | AMINO- IMIDAZOLONES AND THEIR USE AS A MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT, ALZHEIMER DISEASE, NEURODEGENERATION AND DEMENTIA. | AstraZeneca AB (SE) | 2009-03-18 | — | — | EP | disclosed |
| EP-2035424-A1 | AMINO-IMIDAZOLONES AND THEIR USE AS A MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT, ALZHEIMER DISEASE, NEURODEGENERATION AND DEMENTIA. | AstraZeneca AB (SE) | 2009-03-18 | — | — | EP | disclosed |
| US-7504520-B2 | Antagonists of the vanilloid receptor subtype 1 (VR1) and use thereof | ABBOTT LABORATORIES (US) | 2009-03-17 | — | — | US | disclosed |
| US-7498452-B2 | Taxane derivatives functionalized at the 14-position and a process for the preparation thereof | INDENA S.P.A. (IT) | 2009-03-03 | — | — | US | disclosed |
| US-20090023800-A1 | Cannabinoid receptor modulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-01-22 | — | — | US | disclosed |
| US-7479564-B2 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | RAQUALIA PHARMA INC. (JP) | 2009-01-20 | — | — | US | disclosed |
| US-20080312164-A1 | ISOTHIOCYANATES AND GLUCOSINOLATE COMPOUNDS AND ANTI-TUMOR COMPOSITIONS CONTAINING SAME | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2008-12-18 | — | — | US | disclosed |
| US-7465815-B2 | Cannabinoid receptor modulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-16 | — | — | US | disclosed |
| WO-2007145570-A9 | AMINO-IMIDAZOLONES AND THEIR USE AS A MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT, ALZHEIMER DISEASE, NEURODEGENERATION AND DEMENTIA | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | WO | disclosed |
| WO-2007145571-A9 | AMINO-IMIDAZOLONES AND THEIR USE AS A MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT, ALZHEIMER DISEASE, NEURODEGENERATION AND DEMENTIA | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | WO | disclosed |
| WO-2007145569-A9 | AMINO-IMIDAZOLONES AND THEIR USE AS A MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT, ALZHEIMER DISEASE, NEURODEGENERATION AND DEMENTIA | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | WO | disclosed |
| EP-1994030-A1 | MULTI-CYCLIC COMPOUNDS AND METHOD OF USE | Amgen Inc. (US) | 2008-11-26 | — | — | EP | disclosed |
| US-20080261969-A1 | 1,4-Dihydropyridine-Fused Heterocycles, Process for Preparing the Same, Use and Compositions Containing Them | AVENTIS PHARMA S.A. (FR) | 2008-10-23 | — | — | US | disclosed |
| EP-1628969-A4 | BENZOPYRAN DERIVATIVES SUBSTITUTED WITH A BENZIMIDAZOLE DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DONGBU HANNONG CHEMICAL CO LTD (KR) | 2008-10-22 | — | — | EP | disclosed |
| EP-1980557-A2 | Taxane derivatives functionalized at the 14-position and a process for the preparation thereof | Indena S.P.A. (IT) | 2008-10-15 | — | — | EP | disclosed |
| US-20080242694-A1 | Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith | D SIDOCKY NEIL R | 2008-10-02 | — | — | US | disclosed |
| US-20080242694-A1 | Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith | D SIDOCKY NEIL R | 2008-10-02 | — | — | US | disclosed |
| US-20080242694-A1 | Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith | D SIDOCKY NEIL R | 2008-10-02 | — | — | US | disclosed |
| WO-2008063114-A9 | AMINO- IMIDAZOLONES AND THEIR USE AS MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT ALZHEIMER DISEASE, NEURODEGENERATION AND DEMENTIA | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | WO | disclosed |
| US-20080214577-A1 | New Compounds 320 | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | US | disclosed |
| US-7420060-B2 | Benzopyran derivatives substituted with a thioxobenzoxazole derivative, pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them | SCHAEFFLER KG (DE) | 2008-09-02 | — | — | US | disclosed |
| EP-1537093-B1 | TAXANE DERIVATIVES FUNCTIONALIZED AT THE 14- POSITION AND A PROCESS FOR THE PREPARATION THEREOF | INDENA SPA (IT) | 2008-06-11 | — | — | EP | disclosed |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | US | disclosed |
| EP-1910366-A2 | 1,4-DIHYDROPYRIDINE-FUSED HETEROCYCLES, PROCESS FOR PREPARING THE SAME, USE AND COMPOSITIONS CONTAINING THEM | Aventis Pharma S.A. (FR) | 2008-04-16 | — | — | EP | disclosed |
| WO-2008036308-A2 | AMINO-SUBSTITUTED HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-03-27 | — | — | WO | disclosed |
| WO-2008036308-A2 | AMINO-SUBSTITUTED HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-03-27 | — | — | WO | disclosed |
| US-20080058349-A1 | New Compounds 318 | ASTRAZENECA AB (SE) | 2008-03-06 | — | — | US | disclosed |
| EP-1626968-A4 | BENZOPYRAN DERIVATIVES SUBSTITUTED WITH A THIOXOBENZOXAZOLE DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DONGBU HANNONG CHEMICAL CO LTD (KR) | 2008-03-05 | — | — | EP | disclosed |
| US-20080051390-A1 | Imidazole amines as inhibitors of beta-secretase | WYETH (US) | 2008-02-28 | — | — | US | disclosed |
| US-20080051420-A1 | New Compounds 317 | ASTRAZENECA AB (SE) | 2008-02-28 | — | — | US | disclosed |
| US-20080051390-A1 | Imidazole amines as inhibitors of beta-secretase | WYETH (US) | 2008-02-28 | — | — | US | disclosed |
| US-20080051390-A1 | Imidazole amines as inhibitors of beta-secretase | WYETH (US) | 2008-02-28 | — | — | US | disclosed |
| WO-2008022024-A2 | IMIDAZOLE AMINES AS INHIBITORS OF BETA-SECRETASE | WYETH (US) | 2008-02-21 | — | — | WO | disclosed |
| EP-1885704-A2 | ANTAGONISTS OF THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USES THEREOF | Abbott Laboratories (US) | 2008-02-13 | — | — | EP | disclosed |
| US-20080021087-A1 | Cannabinoid receptor modulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2008-01-24 | — | — | US | disclosed |
| EP-1330451-B1 | SUBSTITUTED BENZIMIDAZOL-2-ONES AS VASOPRESSIN RECEPTOR ANTAGONISTS AND NEUROPEPTIDE Y MODULATORS | ORTHO MCNEIL PHARM INC (US) | 2008-01-23 | — | — | EP | disclosed |
| WO-2008008954-A2 | ISOTHIOCYANATES AND GLUCOSINOLATE COMPOUNDS AND ANTI-TUMOR COMPOSITIOS CONTAINING SAME | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2008-01-17 | — | — | WO | disclosed |
| US-20070299087-A1 | New Compounds 319 | ASTRAZENECA AB (SE) | 2007-12-27 | — | — | US | disclosed |
| EP-1870414-A1 | THIENOPYRIDINE DERIVATIVE, OR QUINOLINE DERIVATIVE, OR QUINAZOLINE DERIVATIVE, HAVING C-MET AUTOPHOSPHORYLATION INHIBITING POTENCY | Kirin Pharma Kabushiki Kaisha (JP) | 2007-12-26 | — | — | EP | disclosed |
| WO-2007145571-A1 | AMINO-IMIDAZOLONES AND THEIR USE AS A MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT, ALZHEIMER DISEASE, NEURODEGENERATION AND DEMENTIA | ASTRAZENECA AB (SE) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007145569-A1 | AMINO-IMIDAZOLONES AND THEIR USE AS A MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT, ALZHEIMER DISEASE, NEURODEGENERATION AND DEMENTIA | ASTRAZENECA AB (SE) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007145570-A1 | AMINO-IMIDAZOLONES AND THEIR USE AS A MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT, ALZHEIMER DISEASE, NEURODEGENERATION AND DEMENTIA | ASTRAZENECA AB (SE) | 2007-12-21 | — | — | WO | disclosed |
| US-7309793-B2 | Benzopyran derivatives substituted with a benzimidazole derivative, pharmaceutically acceptable salts therof, their preparations and pharmaceutical compositions containing them | DONGBU HANNONG CHEMICAL CO., LTD. (KR) | 2007-12-18 | — | — | US | disclosed |
| US-20070224607-A1 | Methods for identifying compounds of interest using encoded libraries | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070224607-A1 | Methods for identifying compounds of interest using encoded libraries | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2007-09-27 | — | — | US | disclosed |
| EP-1833806-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | AstraZeneca AB (SE) | 2007-09-19 | — | — | EP | disclosed |
| US-20070213325-A1 | Multi-cyclic compound and method of use | AMGEN INC. (US) | 2007-09-13 | — | — | US | disclosed |
| WO-2007100646-A1 | MULTI-CYCLIC COMPOUNDS AND METHOD OF USE | AMGEN INC. (US) | 2007-09-07 | — | — | WO | disclosed |
| US-20070207998-A1 | Muscarinic Antagonists With Parp and Sir Modulating Activity as Agents for Inflammatory Diseases | PROTEOSYS AG (DE) | 2007-09-06 | — | — | US | disclosed |
| US-20070155732-A1 | Aryl or Heteroaryl Fused Imidazole Compounds as Anti-Inflammatory and Analgesic Agents | PFIZER INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070123618-A1 | Stepwise growth of oligomeric redox-active molecules on a surface without the use of protecting groups | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2007-05-31 | — | — | US | disclosed |
| US-7220777-B2 | Lactam derivatives as antagonists for human 11cby receptors | SMITHKLINE BEECHAM P.L.C. (GB) | 2007-05-22 | — | — | US | disclosed |
| US-20070099990-A1 | Cannabinoid receptor modulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-05-03 | — | — | US | disclosed |
| US-20070093481-A1 | Benzopyran derivatives substituted with a thioxobenzoxazole derivative, pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containingthem | DONGBU HANNONG CHEMICAL CO., LTD. (KR) | 2007-04-26 | — | — | US | disclosed |
| US-20070066618-A1 | Use of EP4 Receptor Ligands in the Treatment of IL-6 Involved Diseases | PFIZER INC. | 2007-03-22 | — | — | US | disclosed |
| EP-1575929-B1 | THE METHOD FOR PRODUCTION OF SEMI-FINISHED PRODUCTS USEFUL IN SYNTHESIS OF PACLITAXEL | AGROPHARM S A (PL) | 2007-03-21 | — | — | EP | disclosed |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | disclosed |
| WO-2007025114-A2 | STEPWISE GROWTH OF OLIGOMERIC REDOX-ACTIVE MOLECULES ON A SURFACE WITHOUT THE USE OF PROTECTING GROUPS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-03-01 | — | — | WO | disclosed |
| EP-1756091-A1 | NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2007-02-28 | — | — | EP | disclosed |
| US-20070042401-A1 | Methods for synthesis of encoded libraries | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070042401-A1 | Methods for synthesis of encoded libraries | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| WO-2007012972-A2 | 1,4-DIHYDROPYRIDINE-FUSED HETEROCYCLES, PROCESS FOR PREPARING THE SAME, USE AND COMPOSITIONS CONTAINING THEM | AVENTIS PHARMA S.A. (FR) | 2007-02-01 | — | — | WO | disclosed |
| US-20060293376-A1 | Benzopyran derivatives substituted with a benzimidazole derviative, pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them | DONGBU HANNONG CHEMICAL CO., LTD. (KR) | 2006-12-28 | — | — | US | disclosed |
| US-20060281799-A1 | Antagonists of the vanilloid receptor subtype 1 (VR1) and use thereof | ABBVIE INC. | 2006-12-14 | — | — | US | disclosed |
| US-7148234-B2 | Use of EP4 receptor ligands in the treatment of IL-6 involved diseases | PFIZER INC. (US) | 2006-12-12 | — | — | US | disclosed |
| US-7141580-B2 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | PFIZER INC. (US) | 2006-11-28 | — | — | US | disclosed |
| WO-2006122250-A2 | ANTAGONISTS OF THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USES THEREOF | ABBOTT LABORATORIES (US) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006064189-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
| US-20060122258-A1 | Taxane derivatives functionalized at the 14-position and a process for the preparation thereof | INDENA S.P.A. (IT) | 2006-06-08 | — | — | US | disclosed |
| EP-1666480-A1 | Aryl or Heteroaryl Fused Imidazole Compounds as intermediates for Anti-Inflammatory And Analgesic Agents. | PFIZER PHARMACEUTICALS INC. (JP) | 2006-06-07 | — | — | EP | disclosed |
| EP-1637527-A1 | CANNABINOID RECEPTOR MODULATOR | Takeda Pharmaceutical Company Limited (JP) | 2006-03-22 | — | — | EP | disclosed |
| EP-1326864-B1 | ARYL OR HETEROARYL FUSED IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | PFIZER PHARMA (JP) | 2006-03-15 | — | — | EP | disclosed |
| EP-1628969-A1 | BENZOPYRAN DERIVATIVES SUBSTITUTED WITH A BENZIMIDAZOLE DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Dongbu Hannong Chemical Co., Ltd. (KR) | 2006-03-01 | — | — | EP | disclosed |
| EP-1626968-A1 | BENZOPYRAN DERIVATIVES SUBSTITUTED WITH A THIOXOBENZOXAZOLE DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Dongbu Hannong Chemical Co., Ltd. (KR) | 2006-02-22 | — | — | EP | disclosed |
| US-20050282907-A1 | Non nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-12-22 | — | — | US | disclosed |
| WO-2005118575-A1 | NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-12-15 | — | — | WO | disclosed |
| WO-2005115147-A2 | HIV REVERSE TRANSCRIPTASE INHIBITORS | MERCK & CO., INC. (US) | 2005-12-08 | — | — | WO | disclosed |
| US-20050256175-A1 | Novel glucagon antagonists/inverse agonists | LAU JESPER | 2005-11-17 | — | — | US | disclosed |
| EP-1575929-A1 | THE METHOD FOR PRODUCTION OF SEMI-FINISHED PRODUCTS USEFUL IN SYNTHESIS OF PACLITAXEL | Agropharm S.A. (PL) | 2005-09-21 | — | — | EP | disclosed |
| US-20050154039-A1 | 5-Sulphanyl-4h-1,2,4-triazole derivatives and their use as medicine | IPSEN PHARMA S.A.S. (FR) | 2005-07-14 | — | — | US | disclosed |
| EP-1537093-A2 | TAXANE DERIVATIVES FUNCTIONALIZED AT THE 14- POSITION AND A PROCESS FOR THE PREPARATION THEREOF | INDENA S.p.A. (IT) | 2005-06-08 | — | — | EP | disclosed |
| US-6881746-B2 | Glucagon antagonists/inverse agonists | NOVO NORDICK A/S (DK) | 2005-04-19 | — | — | US | disclosed |
| EP-1519723-A1 | NOVEL GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2005-04-06 | — | — | EP | disclosed |
| EP-1499305-A2 | USE OF EP4 RECEPTOR LIGANDS IN THE TREATMENT OF IL-6 INVOLVED DISEASES | Pfizer Japan Inc. (JP) | 2005-01-26 | — | — | EP | disclosed |
| WO-2004106330-A1 | BENZOPYRAN DERIVATIVES SUBSTITUTED WITH A BENZIMIDAZOLE DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DONGBU HANNONG CHEMICAL CO., LTD (KR) | 2004-12-09 | — | — | WO | disclosed |
| WO-2004106331-A1 | BENZOPYRAN DERIVATIVES SUBSTITUTED WITH A THIOXOBENZOXAZOLE DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DONGBU HANNONG CHEMICAL CO., LTD (KR) | 2004-12-09 | — | — | WO | disclosed |
| US-20040210063-A1 | Novel 2,4-diaminothiazole derivatives | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | US | disclosed |
| EP-1465880-A1 | 5-SULPHANYL-4H-1,2,4-TRIAZOLE DERIVATIVES AND THEIR USE AS MEDICINE | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-10-13 | — | — | EP | disclosed |
| US-20040181059-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | ASKAT INC. (JP) | 2004-09-16 | — | — | US | disclosed |
| US-20040152740-A1 | Arylglycine derivatives for use as glycine transport inhibitors | NPS ALLELIX CORPORATION (CA) | 2004-08-05 | — | — | US | disclosed |
| EP-1037887-B1 | 5-(2-IMIDAZOLINYLAMINO)-BENZIMIDAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS .ALPHA.-ADRENOCEPTOR AGONISTS WITH IMPROVED METABOLIC STABILITY | PROCTER & GAMBLE (US) | 2004-07-14 | — | — | EP | disclosed |
| WO-2004056790-A1 | THE METHOD FOR PRODUCTION OF SEMI-FINISHED PRODUCTS USEFUL IN SYNTHESIS OF PACLITAXEL | AGROPHARM S.A. (PL) | 2004-07-08 | — | — | WO | disclosed |
| EP-1417188-A1 | NOVEL 2,4-DIAMINOTHIAZOLE DERIVATIVES | Novo Nordisk A/S (DK) | 2004-05-12 | — | — | EP | disclosed |
| WO-2004037166-A2 | THERAPEUTIC GUANIDINES | ISIS PHARMACEUTICALS, INC. (US) | 2004-05-06 | — | — | WO | disclosed |
| WO-2004024706-A2 | TAXANE DERIVATIVES FUNCTIONALIZED AT THE 14- POSITION AND A PROCESS FOR THE PREPARATION THEREOF | INDENA S.P.A. (IT) | 2004-03-25 | — | — | WO | disclosed |
| US-6710054-B2 | CONTAINING SULFONYLAMINOCARBONYL GROUPS; PROSTAGLANDIN INHIBITORS | PFIZER INC | 2004-03-23 | — | — | US | disclosed |
| WO-2004022534-A1 | ARYLGLYCINE DERIVATIVES FOR USE AS GLYCINE TRANSPORT INHIBITORS | NPS ALLELIX CORP. (CA) | 2004-03-18 | — | — | WO | disclosed |
| US-20040014789-A1 | Novel glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2004-01-22 | — | — | US | disclosed |
| WO-2004002480-A1 | NOVEL GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2004-01-08 | — | — | WO | disclosed |
| US-20030236260-A1 | Use of EP4 receptor ligands in the treatment of IL-6 involved diseases | SHIMOJO MASATO | 2003-12-25 | — | — | US | disclosed |
| US-6653478-B2 | Psychological disorders; hypotensive agents | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-11-25 | — | — | US | disclosed |
| WO-2003086371-A2 | USE OF EP4 RECEPTOR LIGANDS IN THE TREATMENT OF IL-6 INVOLVED DISEASES | PFIZER JAPAN INC. (JP) | 2003-10-23 | — | — | WO | disclosed |
| EP-1326864-A2 | ARYL OR HETEROARYL FUSED IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | PFIZER PHARMACEUTICALS INC. (JP) | 2003-07-16 | — | — | EP | disclosed |
| EP-1326606-A2 | EP4 RECEPTOR INHIBITORS TO TREAT RHEUMATOID ARTHRITIS | PFIZER PHARMACEUTICALS INC. (JP) | 2003-07-16 | — | — | EP | disclosed |
| WO-2003045926-A1 | 5-SULPHANYL-4H-1,2,4-TRIAZOLE DERIVATIVES AND THEIR USE AS MEDICINE | SOCIETE DE CONSEILS DE RECHERCHE ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2003-06-05 | — | — | WO | disclosed |
| US-20030073842-A1 | Novel substituted benzimidazol-2-ones as vasopressin receptor antagonists and neuropeptide Y modulators | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-04-17 | — | — | US | disclosed |
| WO-2003011843-A1 | NOVEL 2,4-DIAMINOTHIAZOLE DERIVATIVES | NOVO NORDISK A/S (DK) | 2003-02-13 | — | — | WO | disclosed |
| US-6486190-B1 | 5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as .alpha.-adrenoceptor agonists with improved metabolic stability | THE PROCTER & GAMBLE COMPANY | 2002-11-26 | — | — | US | disclosed |
| US-20020107273-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | ASKAT INC. (JP) | 2002-08-08 | — | — | US | disclosed |
| US-20020077329-A1 | EP4 receptor inhibitors to treat rheumatoid arthritis | PFIZER PHARMACEUTICALS INC. (JP) | 2002-06-20 | — | — | US | disclosed |
| WO-2002032422-A2 | EP4 RECEPTOR INHIBITORS TO TREAT RHEUMATOID ARTHRITIS | PFIZER PHARMACEUTICALS INC. (JP) | 2002-04-25 | — | — | WO | disclosed |
| WO-2002032900-A2 | ARYL OR HETEROARYL FUSED IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | PFIZER PHARMACEUTICALS INC. (JP) | 2002-04-25 | — | — | WO | disclosed |
| EP-0842174-B1 | HETEROCYCLIC COMPOUNDS FOR TREATING MYOCARDIAL ISCHAEMIA | PF MEDICAMENT (FR) | 2001-10-04 | — | — | EP | disclosed |
| EP-1037887-A1 | 5-(2-IMIDAZOLINYLAMINO)-BENZIMIDAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS .ALPHA.-ADRENOCEPTOR AGONISTS WITH IMPROVED METABOLIC STABILITY | THE PROCTER & GAMBLE COMPANY (US) | 2000-09-27 | — | — | EP | disclosed |
| EP-0736020-B1 | 6-(2-IMIDAZOLINYLAMINO)QUINOLINE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS | PROCTER & GAMBLE (US) | 2000-04-26 | — | — | EP | disclosed |
| EP-0975627-A1 | 5-(2-IMIDAZOLINYLAMINO)BENZIMIDAZOLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 2000-02-02 | — | — | EP | disclosed |
| US-6011032-A | Heterocyclic compounds for treating myocardial ischemia | PIERRE FABRE MEDICAMENT (FR) | 2000-01-04 | — | — | US | disclosed |
| EP-0934940-A1 | CYTOKINE PRODUCTION INHIBITORS, TRIAZEPINE COMPOUNDS, AND INTERMEDIATES THEREOF | Japan Tobacco Inc. (JP) | 1999-08-11 | — | — | EP | disclosed |
| WO-1999026942-A1 | 5-(2-IMIDAZOLINYLAMINO)-BENZIMIDAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS .ALPHA.-ADRENOCEPTOR AGONISTS WITH IMPROVED METABOLIC STABILITY | THE PROCTER & GAMBLE COMPANY (US) | 1999-06-03 | — | — | WO | disclosed |
| EP-0510356-B1 | Polyethylene glycol protein conjugates | HOFFMANN LA ROCHE (CH) | 1999-01-27 | — | — | EP | disclosed |
| US-5849860-A | Polyethylene-protein conjugates | HOFFMANN-LA ROCHE INC. (US) | 1998-12-15 | — | — | US | disclosed |
| US-5834594-A | WATER SOLUBLE NONIMMUNOGENIC CONJUGATE WHICH DOES NOT HAVE SAME PROPERTIES OF PRODUCING AN IMMUNOGENIC RESPONSE POSSESSED BY THE PROTEIN WHICH FORMS THE CONJUGATE | HOFFMAN-LA ROCHE INC. (US) | 1998-11-10 | — | — | US | disclosed |
| WO-1998046595-A1 | 5-(2-IMIDAZOLINYLAMINO)BENZIMIDAZOLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 1998-10-22 | — | — | WO | disclosed |
| US-5807850-A | Therapeutic agent for osteoporosis and triazepine compound | JAPAN TOBACCO, INC. (JP) | 1998-09-15 | — | — | US | disclosed |
| US-5804587-A | 6-(2-imidazolinylamino) quinolines useful as alpha-2 adrenoceptor agonists | THE PROCTER & GAMBLE COMPANY (US) | 1998-09-08 | — | — | US | disclosed |
| US-5792834-A | Polyethylene-protein conjugates | HOFFMANN-LA ROCHE INC. (US) | 1998-08-11 | — | — | US | disclosed |
| US-5776907-A | INHIBITORS OF GENE PRODUCT EXPRESSION | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1998-07-07 | — | — | US | disclosed |
| US-5767256-A | REACTING HYDROXYL GROUP-CONTAINING ACCEPTOR WITH DONOR SELECTED FROM O-PYRANOSYL AND O-FURANOSYL GLYCOSIDES HAVING PYRIDINE-CONTAINING LEAVING GROUPS | HANESSIAN STEPHEN (CA) | 1998-06-16 | — | — | US | disclosed |
| EP-0842174-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING MYOCARDIAL ISCHAEMIA | PIERRE FABRE MEDICAMENT (FR) | 1998-05-20 | — | — | EP | disclosed |
| US-5747646-A | THIOUREA-LINKED POLYOXYETHYLENE GLYCOL; NONIMMUNOGENIC | HOFFMANN-LA ROCHE INC. (US) | 1998-05-05 | — | — | US | disclosed |
| US-5739148-A | RESPIRATORY SYSTEM DISORDERS, GASTROINTESTINAL DISORDERS, VISION DISORDERS | THE PROCTER & GAMBLE COMPANY | 1998-04-14 | — | — | US | disclosed |
| EP-0792880-A1 | OSTEOPOROSIS REMEDY AND TRIAZEPINE COMPOUND | Japan Tobacco Inc. (JP) | 1997-09-03 | — | — | EP | disclosed |
| US-5663189-A | RESPIRATORY, EYES, GASTROINTESTINAL | THE PROCTER & GAMBLE COMPANY (US) | 1997-09-02 | — | — | US | disclosed |
| WO-1997005134-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING MYOCARDIAL ISCHAEMIA | PIERRE FABRE MEDICAMENT (FR) | 1997-02-13 | — | — | WO | disclosed |
| US-5595732-A | INTERFERON CONJUGATES WITH HYDROXYETHYLUREA AND POLYOXYETHYLENE GLYCOL | HOFFMANN-LA ROCHE INC. (US) | 1997-01-21 | — | — | US | disclosed |
| US-5578607-A | 6-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists | THE PROCTER & GAMBLE COMPANY (US) | 1996-11-26 | — | — | US | disclosed |
| US-5559213-A | INTERLEUKINS | HOFFMANN-LA ROCHE INC. (US) | 1996-09-24 | — | — | US | disclosed |
| US-5539063-A | WITHOUT IMMUNOGENIC RESPONSE, PYRIDINYLOXY THIOCARBONYL AMINO CONTAINING END GROUP | HOFFMANN-LA ROCHE INC. (US) | 1996-07-23 | — | — | US | disclosed |
| US-5534440-A | ISOTHIOCYANATE, IONIZABLE GROUP | BIOMEDICAL RESEARCH CENTRE LIMITED (CA) | 1996-07-09 | — | — | US | disclosed |
| WO-1996016077-A2 | REAGENT FOR QUANTIFYING FREE AMINE GROUPS | AGOURON PHARMACEUTICALS, INC. (US) | 1996-05-30 | — | — | WO | disclosed |
| US-5510245-A | COLORIMETRIC, QUALITATIVE, QUANTITATIVE ANALYSIS OF BETA-HYDROXYBUTYRIC ACID WITH DEHYDROGENASE, NAD, A DISULFIDE SUBSTRATE, A DISULFIDE REDUCTASE AND THIOL-RESPONSIVE INDICATOR DYE; TREATING DIABETES | BAYER CORPORATION (US) | 1996-04-23 | — | — | US | disclosed |
| EP-0463524-B1 | Composition and method of assaying for ketone bodies | BAYER AG (US) | 1996-03-06 | — | — | EP | disclosed |
| US-5436240-A | Schizophrenia, Parkinson's disease, depression or hypotensive agents using tricyclic amines | THE UPJOHN COMPANY (US) | 1995-07-25 | — | — | US | disclosed |
| WO-1995003316-A2 | SOLUTION AND SOLID PHASE STEREOCONTROLLED GLYCOSIDATION | HANESSIAN STEPHEN (CA) | 1995-02-02 | — | — | WO | disclosed |
| EP-0480939-B1 | HETEROCYCLIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY | UPJOHN CO (US) | 1995-01-25 | — | — | EP | disclosed |
| WO-1994026715-A1 | AMIDINE DERIVATIVES AS GASTRIC ACID SECRETION INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 1994-11-24 | — | — | WO | disclosed |
| EP-0605963-A2 | Peg hydrazone and peg oxime linkage forming reagents and protein derivatives thereof | ORTHO PHARMACEUTICAL CORPORATION (US) | 1994-07-13 | — | — | EP | disclosed |
| US-5326697-A | NAD, hydroxybutyrate dehydrogenase, cystine reductase, cystine indicator dye | MILES INC. (US) | 1994-07-05 | — | — | US | disclosed |
| US-5273975-A | Heterocyclic amines having central nervous system activity | THE UPJOHN COMPANY (US) | 1993-12-28 | — | — | US | disclosed |
| US-5242939-A | Hypotensive | WARNER-LAMBERT COMPANY (US) | 1993-09-07 | — | — | US | disclosed |
| US-5190863-A | Composition for determining the presence or concentration of D-β-hydroxybutyrate | MILES INC. (US) | 1993-03-02 | — | — | US | disclosed |
| EP-0510356-A1 | Polyethylene glycol protein conjugates | F. HOFFMANN-LA ROCHE AG (CH) | 1992-10-28 | — | — | EP | disclosed |
| EP-0480939-A1 | HETEROCYCLIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY. | UPJOHN CO (US) | 1992-04-22 | — | — | EP | disclosed |
| WO-1992006081-A1 | ANILIDE DERIVATIVES WITH ANGIOTENSIN II ANTAGONIST PROPERTIES | WARNER-LAMBERT COMPANY (US) | 1992-04-16 | — | — | WO | disclosed |
| EP-0463524-A1 | Composition and method of assaying for ketone bodies | Bayer Corporation (US) | 1992-01-02 | — | — | EP | disclosed |
| US-5045540-A | Amide or urea compounds containing imidazole groups | WARNER-LAMBERT CO. (US) | 1991-09-03 | — | — | US | disclosed |
| US-5041552-A | Treatment of hypertension, heart failure, glaucoma and hyperaldosteronism | WARNER-LAMBERT COMPANY (US) | 1991-08-20 | — | — | US | disclosed |
| WO-1990015058-A1 | HETEROCYCLIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY | THE UPJOHN COMPANY (US) | 1990-12-13 | — | — | WO | disclosed |
| WO-1990015058-A1 | HETEROCYCLIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY | THE UPJOHN COMPANY (US) | 1990-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022527-A1 | BIPHENYL SUBSTITUTED SPIROTETRONIC ACIDS AND THEIR USE FOR THE TREATMENT OF RETROVIRAL DISEASES | DHFR, RORA, CYP2A6 | KDM4E 3591/4885LMNA 1617/4885CCR1 184/4885 |
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | DGAT1, DGAT2, GPR119 | KDM4E 3511/4885LMNA 3296/4885CCR1 3249/4885 |
| US-20240124780-A1 | HETEROAROMATIC ISOTHIOCYANATES | TRPA1, CRY1, FOXM1 | KDM4E 3590/4885LMNA 2725/4885CCR1 1117/4885 |
| US-20040014789-A1 | Novel glucagon antagonists/inverse agonists | GLP1R, GCGR, GIPR | KDM4E 3489/4885LMNA 4123/4885CCR1 3662/4885 |
| US-20120309755-A1 | NOVEL COMPOUNDS | PTGER1, PTGS1, PTGES | KDM4E 3379/4885LMNA 1816/4885CCR1 557/4885 |
| US-20070299087-A1 | New Compounds 319 | PSEN2, PSEN1, MAPT | KDM4E 3116/4885LMNA 2545/4885CCR1 4626/4885 |
| US-20220185803-A1 | MACROCYCLIC COMPLEXES OF ALPHA-EMITTING RADIONUCLIDES AND THEIR USE IN TARGETED RADIOTHERAPY OF CANCER | PSMA1, FOLH1, KLK3 | KDM4E 2583/4885LMNA 3918/4885CCR1 2324/4885 |
| US-20170253565-A1 | OPIOID AGONISTS AND USES THEREOF | OPRM1, OPRK1, OPRD1 | KDM4E 3977/4885LMNA 4068/4885CCR1 613/4885 |
| US-20080261969-A1 | 1,4-Dihydropyridine-Fused Heterocycles, Process for Preparing the Same, Use and Compositions Containing Them | DPYD, DHPS, QDPR | KDM4E 1534/4885LMNA 1573/4885CCR1 1502/4885 |
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | WNK3, REN, SGK3 | KDM4E 2949/4885LMNA 2006/4885CCR1 2142/4885 |
| US-20120309738-A1 | NOVEL COMPOUNDS | PTGER1, PTGS1, PTGES | KDM4E 3184/4885LMNA 2657/4885CCR1 670/4885 |
| US-20120196897-A1 | NEW COMPOUNDS | MTX1, LTB4R, RDX | KDM4E 2615/4885LMNA 1740/4885CCR1 468/4885 |
| US-20250179364-A1 | ISOTHIOCYANATOETHYNYLBENZENE DERIVATIVES | CCNB1, CDC25B, MCM4 | KDM4E 4224/4885LMNA 2429/4885CCR1 723/4885 |
| US-20170022167-A1 | OPIOID AGONISTS AND USES THEREOF | OPRM1, OPRK1, OPRD1 | KDM4E 3977/4885LMNA 4068/4885CCR1 613/4885 |
| US-10363239-B2 | Method for inhibiting growth of cancer cells | FLNA, FLNB, FSCN1 | KDM4E 3556/4885LMNA 1109/4885CCR1 3411/4885 |
| US-20100168091-A1 | Imidazole Amines As Inhibitors Of Beta-secretase | BACE1, BACE2, APP | KDM4E 1564/4885LMNA 686/4885CCR1 4872/4885 |
| US-20250360218-A1 | MITOCHONDRIA-TARGETING CANCER THERAPEUTIC COMPOSITION | TSPO, TFAM, MCU | KDM4E 1419/4885LMNA 1398/4885CCR1 4442/4885 |
| US-20250206737-A1 | PROCESS FOR PREPARING TUCATINIB AND ITS HEMIETHANOLATE | TALDO1, UGT1A3, ADH1C | KDM4E 691/4885LMNA 3648/4885CCR1 3334/4885 |
| US-20220274974-A1 | MACROCYCLIC COMPLEXES OF ALPHA-EMITTING RADIONUCLIDES AND THEIR USE IN TARGETED RADIOTHERAPY OF CANCER | PSMA1, KLK3, FOLH1 | KDM4E 1802/4885LMNA 3834/4885CCR1 2491/4885 |
| US-20220267312-A1 | AMINO BENZOTHIAZOLE COMPOUNDS FOR TREATMENT OF ANTIBIOTIC RESISTANT BACTERIA | BCAT2, BCAT1, ABAT | KDM4E 1468/4885LMNA 3561/4885CCR1 4730/4885 |
| US-20240072425-A1 | AROMATIC ISOTHIOCYANATES | TRPA1, TRPC1, CRY1 | KDM4E 2656/4885LMNA 2735/4885CCR1 305/4885 |
| US-20090270391-A1 | THIENOPYRIDINE DERIVATIVE, OR QUINOLINE DERIVATIVE, OR QUINAZOLINE DERIVATIVE, HAVING c-MET AUTOPHOSPHORYLATION INHIBITING POTENCY | MET, ABL1, RET | KDM4E 1038/4885LMNA 4095/4885CCR1 2244/4885 |
| US-20220177461-A1 | MACROCYCLIC COMPLEXES OF ALPHA-EMITTING RADIONUCLIDES AND THEIR USE IN TARGETED RADIOTHERAPY OF CANCER | PSMA1, FOLH1, KLK3 | KDM4E 2583/4885LMNA 3918/4885CCR1 2324/4885 |
| US-20190136184-A1 | METHOD OF INHIBITING TAU PHOSPHORYLATION | FLNA, FLNB, MAPT | KDM4E 2906/4885LMNA 104/4885CCR1 2449/4885 |
| US-20040152740-A1 | Arylglycine derivatives for use as glycine transport inhibitors | SLC1A2, SLC6A7, SLC1A1 | KDM4E 3734/4885LMNA 3700/4885CCR1 1723/4885 |
| US-12570647-B2 | Amino benzothiazole compounds for treatment of antibiotic resistant bacteria | BCAT1, BCAT2, IL4I1 | KDM4E 3664/4885LMNA 1975/4885CCR1 390/4885 |
| US-20070213325-A1 | Multi-cyclic compound and method of use | TIE1, CDK1, CCNB1 | KDM4E 397/4885LMNA 1829/4885CCR1 1033/4885 |
| US-11045560-B2 | Therapeutic conjugates with sulfated dendrimers for intracellular targeting | CD44, SELE, SLC10A6 | KDM4E 4440/4885LMNA 2326/4885CCR1 1734/4885 |
| US-20060281799-A1 | Antagonists of the vanilloid receptor subtype 1 (VR1) and use thereof | TRPV1, TMEM109, CACNA1E | KDM4E 3803/4885LMNA 1886/4885CCR1 334/4885 |
| US-12378224-B2 | Heteroaryl compounds and their use as Mer inhibitors | MERTK, RET, ERBB2 | KDM4E 1635/4885LMNA 1144/4885CCR1 3209/4885 |
| US-20130142739-A1 | PROCESS FOR THE SYNTHESIS OF ISOTHIOCYANATES AND DERIVATIVES THEREOF AND USES OF SAME | TST, CBS, SRM | KDM4E 2039/4885LMNA 4543/4885CCR1 2312/4885 |
| US-20170182193-A1 | THERAPEUTIC CONJUGATES WITH SULFATED DENDRIMERS FOR INTRACELLULAR TARGETING | CD44, SLC10A6, SELE | KDM4E 4459/4885LMNA 2458/4885CCR1 1738/4885 |
| US-20190300507-A1 | TRIAZOLE PYRIDYL COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | TBXA2R, AGTR1, APLNR | KDM4E 4443/4885LMNA 2502/4885CCR1 2182/4885 |
| US-20150329522-A1 | MELANOCORTIN RECEPTOR ANTAGONIST COMPOUNDS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS | MC1R, MC5R, MC3R | KDM4E 3425/4885LMNA 3243/4885CCR1 482/4885 |
| US-20140296204-A1 | CHEMICAL COMPOUNDS | DNMT1, DNMT3A, DNMT3B | KDM4E 42/4885LMNA 1670/4885CCR1 3215/4885 |
| US-20130012518-A1 | BICYCLIC COMPOUNDS AND THEIR USES AS DUAL C-SRC / JAK INHIBITORS | JAK2, SRC, JAK1 | KDM4E 1224/4885LMNA 4805/4885CCR1 927/4885 |
| US-20250376432-A1 | PROCESS FOR PREPARING MODULATORS OF EUKARYOTIC INITIATION FACTOR 2B | EIF4EBP1, EIF2B1, EIF4A2 | KDM4E 2997/4885LMNA 2149/4885CCR1 4257/4885 |
| US-20110275829-A1 | Androgen receptor modulating compounds, preparation and uses thereof | AR, NR5A1, SHBG | KDM4E 2454/4885LMNA 3967/4885CCR1 2637/4885 |
| US-10760052-B2 | Method of inhibiting tau phosphorylation | FLNA, FLNB, MAPT | KDM4E 2906/4885LMNA 104/4885CCR1 2449/4885 |
| US-20110312935-A1 | 1H-Benz Imidazole-5-Carboxamides As Anti-Inflammatory Agents | MAPRE2, MAPRE1, H1-4 | KDM4E 140/4885LMNA 2823/4885CCR1 2049/4885 |
| US-20160176845-A1 | PROCESS FOR THE PREPARATION OF A DIARYLTHIOHYDANTOIN COMPOUND | BPHL, CYP4X1, KLK3 | KDM4E 863/4885LMNA 1758/4885CCR1 3824/4885 |
| US-20180362468-A1 | OPIOID AGONISTS AND USES THEREOF | OPRM1, OPRK1, OPRD1 | KDM4E 3977/4885LMNA 4068/4885CCR1 613/4885 |
| US-20060122258-A1 | Taxane derivatives functionalized at the 14-position and a process for the preparation thereof | TUBA1B, TUBB2B, TUBB3 | KDM4E 1525/4885LMNA 2085/4885CCR1 3039/4885 |
| US-20110144057-A1 | ANTAGONISTS OF THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USE THEREOF | TRPV1, TMEM109, CACNA1E | KDM4E 3803/4885LMNA 1886/4885CCR1 334/4885 |
| US-20080312164-A1 | ISOTHIOCYANATES AND GLUCOSINOLATE COMPOUNDS AND ANTI-TUMOR COMPOSITIONS CONTAINING SAME | GGCT, GSTK1, GCLC | KDM4E 1796/4885LMNA 4495/4885CCR1 2669/4885 |
| US-20160176844-A1 | PROCESSES FOR THE PREPARATION OF A DIARYLTHIOHYDANTOIN COMPOUND | BPHL, CYP4X1, KLK3 | KDM4E 1091/4885LMNA 1559/4885CCR1 3903/4885 |
| US-20080214577-A1 | New Compounds 320 | PSEN1, PSEN2, MAPT | KDM4E 3354/4885LMNA 2383/4885CCR1 4552/4885 |
| US-20100105673-A1 | SUBSTITUTED AMINOFURANONES AND THEIR USE | FANCF, TPMT, AAAS | KDM4E 852/4885LMNA 1968/4885CCR1 3417/4885 |
| US-20110251089-A1 | METHODS FOR SYNTHESIS OF ENCODED LIBRARIES | RNGTT, DTYMK, DUT | KDM4E 4000/4885LMNA 3319/4885CCR1 2847/4885 |
| US-20050154039-A1 | 5-Sulphanyl-4h-1,2,4-triazole derivatives and their use as medicine | SSTR3, SSTR1, SSTR5 | KDM4E 3288/4885LMNA 3839/4885CCR1 391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.